№ 02 (150) 2018

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

№ 02 (150) 2018

EDITORIAL

Труд доктора – действительно самый производительный труд:
предохраняя или восстанавливая здоровье,
доктор приобретает обществу все те силы,
которые погибли бы без его забот.
Н. Г. Чернышевский

Уважаемые коллеги !
Забота о сохранении и приумножении знаний, стремлении помочь коллегам поделиться
профессиональным мнением и накопленным опытом, результатами экспериментальных и клинических исследований, побудило авторов очередного выпуска нашего журнала к его созданию. Традиционно один из номеров журнала посвящен актуальным вопросам гепатологии и патологии билиарного тракта.
Оставаясь верными сложившимся традициям, номер открывает передавая статья группы авторов Селиверстов П. В., Ситкин С. И., Радченко В. Г. и другие, посвященная актуальной проблеме гепатологии – неалкогольной жировой болезни печени (НАЖБП). В своей работе авторы демонстрируют возможности профилактики прогрессирования заболевания, воздействуя на одно из звеньев патогенеза, кишечный микробиоценоз,
используя S. Boulardii. Прием S. Boulardii значимо снижал исходно повышенный уровень Escherichia coli, уменьшая риск дополнительного поражения печени эндогенным алкоголем, а также уровень группы Bacteroides fragilis, и как следствие, риск эндотоксемии. Отсутствие признаков прогрессирования заболевания через 90 дней свидетельствовало об эффективности предлагаемой схемы лечения и профилактики у пациентов НАЖБП на стадии стеатоза.
Продолжает эту тему оригинальная работа авторов Журавлевой Л. В., Огневой Е. В. из Харькова посвященная влиянию резистина на липидный метаболизм у больных с НАЖБП с нормальной массой тела и ожирением. Показано, что повышение уровня резистина может отражать наличие дислипидемии у больных с НАЖБП с ожирением и без него, а также даны практические рекомендации.
В свою очередь, изучение диагностической информативности эластографии и эластометрии сдвиговой волной в оценке выраженности фиброза при диффузных заболеваний печени, позволило коллективу авторов из Чувашии показать диагностическую значимость используемого ими способа.
Следующая работа от исследователей из Петрозаводска, под руководством профессора Дудановой О. П., посвящена сравнительному анализу клинико-лабораторных показателей носителей разных генотипов по полиморфному маркеру –174G>C гена IL6 (rs1800795) в группах здоровых доноров и пациентов с НАСГ в отсутствие гепатопротекторной терапии и на фоне терапии УДХК. В результате показано, что наличие однонуклеотидной замены –174G>C в гене IL6 (rs1800795), ассоциированной с развитием НАСГ, может определять не только генетическую предрасположенность к развитию данного заболевания, но и различную чувствительность пациентов с НАЖБП к УДХК.
Продолжая поиск усовершенствования диагностики и лечения НАСГ, авторы Звягинцева Т. Д. и Глущенко С. В. из Харькова, выявив наличие карнитиновой недостаточности, гипергомоцистеинемии, повышение уровня провоспалительных цитокинов у всех пациентов с НАСГ. Они предлогают использовать в комплексной терапии препарат L-карнитина и фолиевой кислоты, что позволят устранить карнитиновую недостаточность, гипергомоцистеинемию, снизить активность провоспалительных цитокинов и, как следствие улучшить клиническую картину заболевания.
Следующая работа посвящена профилактике НАЖБП у пациентов с желчекаменной болезнью после холецистэктомии. По данным авторов у 21,6% больных уже через год после холецистэктомии по данным ультразвукового исследования печени впервые выявляются признаки НАЖБП, что требует разработки адекватных схем профилактики.
Также, работа Деговцова Е. Н. и соавторов, была направлена на изучение отдаленных результатов хирургического лечении у больных холецистохолангиолитиазом. Полученные ими результаты свидетельствуют о несомненном преимуществе одноэтапного минимально инвазивного хирургического лечения больных холецистохолангиолитиазом.

Продолжая тему желчекаменной болезни, в статье Оганезовой И. А. и соавторов приведены данные о ее распространённости и клинических проявлениях, а также отмечена связь патологии желчевыводящих путей с изменениями деятельности сердечно-сосудистой системы, описана клиническая картина холецистокардиального синдрома и тактика ведения больного с данной патологией. Далее, Палатова Л. Ф. и соавторы, делятся с читателем пред эволюцией взглядов на проблемы желчекаменной болезни на примере Пермского края.
Опытом ведения 30-летней больной с лекарственным поражением печени с тяжелым течением делятся сотрудники кафедры под руководством Гриневича В. Б.
В статье Губергриц Н. Б. и соавторов проведен анализ данных о роли физической активности, снижения массы тела при НАЖБП. Особое внимание уделено рекомендациям по питанию с вариантами гипокалорийных диет, представлен алгоритм изменения образа жизни, повышения физической активности и диетического питания, направленный на снижение массы тела и лечение заболевания. В свою очередь, учитывая высокий нутриционный риск у пациентов с правосторонней гемигепатэктомией, коллективом московских авторов проводилась разработка нутриционной коррекции с включением смеси с гепатопротекторным составом, а также ферментов, электролитных растворов, витаминов и пр. Использование подобного подхода в питании способствовало поддержанию удовлетворительного состояния больных.
Изучению уровня простагландинов и их динамику на фоне дифференцированных методов коррекции асцита и гепаторенального синдрома у больных циррозом печени была посвящена работа авторов из Ужгородського национального университета.
Продолжая тему поиска новых методов лечения цирроза печени, целью исследования коллектива авторов из Белоруссии, было определение эффективности и безопасность внутрипеченочной трансплантации мезенхимальных стволовых клеток при хронической ВГС-инфекции на стадии цирроза. В работе Коткас И. Г. и соавторов была произведена оценка изменений биохимических показателей крови у пациентов с циррозом
печени на фоне использования аутологичных мезенхимальных стволоых клеток.
Раздел хирургической гастроэнтерологии представлен работой по оптимизации мониторинга концентраций эверолимуса у пациентов после трансплантации сердца на фоне патологии печени. Авторы в очередной раз демонстрируют, что НАЖБП у пациентов после трансплантации сердца, значительно влияет на фармакокинетику препаратов, достижение целевых значений, что ухудшает прогноз заболевания и качество жизни.
В разделе экспериментальной гастроэнтерологии речь идет о состоянии показателей системы гемостаза у крыс с ацетаминофен-индуцированным гепатитом в условиях алиментарной депривации протеина. Практические аспекты нарушений внутрипеченочной микроциркуляции при хронических заболеваниях печени на начальных стадиях фиброза и возможности их коррекции, освещены в статье Ермоловой Т. В. и соавторов. Также, о перспективах персонализации фармакотерапии портальной гипертензии у больных с циррозом печени, ведет речь Парусов А. И.
Опытом ведения детей страдающих заболеванием печени, вызванным А1-антитрипсиновой недостаточностью, в разделе «Лекция», делятся ведущие педиатры из Санкт-Петербурга: Власов Н. Н., Корниенко Е. А., Мельник С. И.
Особое место в настоящем номере занимают обзоры посвященные роли адипоцитокинов, грелина и инкретинов в предикции НАЖБП и ее лечении у пациентов с СД2 типа, составленные под руководством Бабенко А. Ю., и обзор посвящен вопросам клинической картины, подходам к диагностике и терапии синдрома и болезни Кароли, выполненный Скворцовым В. В.
28 января 2018 года ушел из жизни «…оптимист, живущий под знаменем любви к своему делу, обреченный на успех. Над ним не властны ветра перемен, а новые веяния дают такому специалисту повод подняться на более высокий профессиональный уровень…» именно так писали современники о знаменитом отечественном ученом Николае Алексеевиче Мухине, памятная статья о котором завершает наш номер.
Желаем вам интересного и полезного прочтения!
Ответственный за выпуск редактор,

	Профессор, заведующий кафедрой внутренних болезней и нефрологии СЗГМУ им. И. И. Мечникова доктор медицинских наук
	*В. Г. Радченко*

1.Title page: SACCHAROMYCES BOULARDII MODULATES THE COMPOSITION OF THE GUT MICROBIOTA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE, THUS PREVENTING THE PROGRESSION OF THE DISEASE
Seliverstov P.V.¹, Sitkin S.I. ^1,2 📧 . , Radchenko V.B.¹, Lazebnik L.B.³, Avalueva E.B.¹, Vakhitov T.Ya.², Demyanova E.V.², Skvortsova T.E.¹, Prikhodko E.M.¹, Suvorova M.A.⁴
1. North–Western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
2. State Research Institute of Highly Pure Biopreparations of FMBA of Russia (St. Petersburg, Russian Federation)
3. A. I. Yevdokimov Moscow State University of Medicine and Dentistry (Moscow, Russian Federation)
4. Institute of Experimental Medicine (St. Petersburg, Russian Federation)
Keywords:Bacteroides fragilis group,butyrate,butyric acid,dysbiosis,Escherichia coli,gut microbiota,NAFLD,non-alcoholic fatty liver diseasepsyllium,Saccharomyces boulardii,steatosis

Abstract:25 adult patients with NAFLD (steatosis only) were enrolled in the study. The quantitative real-time polymerase chain reaction (qRT-PCR) was used for fecal microbiota assessment. All patients were treated with oral lyophilized Saccharomyces boulardii for 90 days (3 capsules 250 mg per day). The count of Escherichia coli in patients with NAFLD steatosis was initially higher than the reference values obtained from healthy volunteers. Lyophilized S. boulardii for 90 days significantly reduced Bacteroides fragilis group and Escherichia coli. There were no significant changes in other fecal microbiota (total bacterial count, Lactobacillus group, Bifidobacterium spp., Faecalibacterium prausnitzii, etc.). Treatment with S. boulardii improved symptoms and quality of life in patients with NAFLD steatosis and significantly reduced VLDL and atherogenic index. Patients with overweight or obesity showed a decrease in body weight. In all patient steatosis showed no progression as assessed by FibroMax test, liver ultrasonography and telomere test Saccharomyces boulardii significantly reduced initially elevated fecal Escherichia coli in patients with NAFLD steatosis to normal values, thus reducing the risk of additional liver damage by endogenous ethanol and inhibiting the choline deficiency. S. boulardii significantly lowered Bacteroides fragilis group, thus reducing the risk of endotoxemia. The lack of progression of steatosis after 90 days suggests the effectiveness of S. boulardii in patients with NAFLD. Lyophilized Saccharomyces boulardii modulates the composition of the gut microbiota in patients with NAFLD steatosis and restores intestinal barrier integrity, thus preventing the progression of the disease.
- References total 73 ⇓ :: .
  1. Radchenko V. G., Shabrov A. V., Zinov’eva E.N., Sitkin S. I.Zabolevaniia pecheni i zhelchevyvodiashchikh putei: rukovodstvo dlia vrachei. St. Petersburg, SpetsLit, 2011. [In Russian]
  2. Lazebnik L. B., Radchenko V. G., Golovanova Е. V., Zvenigorodskaya L. A., Konev Yu.V., Seliverstov P. V., Sitkin S. I., Tkachenko E. I., Avaluyeva E. B., Aylamazyan E. K., Vlasov N. N., Grinevich V. B., Korniyenko E. A., Novikova V. P., Khoroshinina L. P., Zhestkova N. V., Oreshko L. S., Dudanova O. P., Dobritsa V. P., Tur’yeva L.V., Tirikova O. V., Kozlova N. M., Yeliseyev S. M., Gumerov R. R., Ventsak E. V., Aleshina E. I., Gurova M. M., Goryacheva L. G. Nonalcoholic fatty liver disease: Clinic, diagnostics, treatment (Recommendations for therapists, 2nd edition). Eksp Klin Gastroenterol. 2017;(2):22–37. [In Russian]
  3. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005 Feb;288(2): E462–8. doi: 10.1152/ajpendo.00064.2004.
  4. Reddy JK, Rao MS. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5): G852–8. doi: 10.1152/ajpgi.00521.2005.
  5. Mekhtiev S. N., Grinevich V. B., Kravchuk Iu.A., Brashchenkova A. V. Non-alcoholic fatty liver disease: A clinical presentation, diagnosis and treatment. Lechashchii vrach. 2008;(2):29–37. [In Russian]
  6. Day CP, James OF. Steatohepatitis: a tale of two «hits»? Gastroenterology. 1998 Apr;114(4):842–5. doi: 10.1016/S0016–5085(98)70599–2.
  7. Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017 Aug 2;4(8). pii: E66. doi: 10.3390/children4080066.
  8. Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol. 2013 May;58(5):1020–7. doi: 10.1016/j.jhep.2012.11.023.
  9. Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, Molina J, Paris A, Want EJ, de Waziers I, Cloarec O, Richards SE, Wang Y, Dumas ME, Ross A, Rezzi S, Kochhar S, Van Bladeren P, Lindon JC, Holmes E, Nicholson JK. Colonization-induced host-gut microbial metabolic interaction. MBio. 2011 Mar 1;2(2): e00271–10. doi: 10.1128/mBio.00271–10.
  10. Quigley EM, Monsour HP. The Gut Microbiota and Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2015 Aug;35(3):262–9. doi: 10.1055/s-0035–1562946.
  11. Miele L, Marrone G, Lauritano C, Cefalo C, Gasbarrini A, Day C, Grieco A. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des. 2013;19(29):5314–24. doi: 10.2174/1381612811319290011.
  12. de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2017 Sep 5. doi: 10.1007/s00394–017–1524-x.
  13. Romano KA, Martinez-Del Campo A, Kasahara K, Chittim CL, Vivas EI, Amador-Noguez D, Balskus EP, Rey FE. Metabolic, Epigenetic, and Transgenerational Effects of Gut Bacterial Choline Consumption. Cell Host Microbe. 2017 Sep 13;22(3):279–290.e7. doi: 10.1016/j.chom.2017.07.021.
  14. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011 Apr 7;472(7341):57–63. doi: 10.1038/nature09922.
  15. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, Fodor AA. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011 Mar;140(3):976–86. doi: 10.1053/j.gastro.2010.11.049.
  16. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect. 2013 Apr;19(4):338–48. doi: 10.1111/1469–0691.12140.
  17. Yu J, Marsh S, Hu J, Feng W, Wu C. The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterol Res Pract. 2016;2016:2862173. doi: 10.1155/2016/2862173.
  18. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2015 Nov;42(9):1051–63. doi: 10.1111/apt.13376.
  19. Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):375–381. doi: 10.1016/S1499–3872(17)60019–5.
  20. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC, Nelson KE. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab. 2017 May 2;25(5):1054–1062.e5. doi: 10.1016/j.cmet.2017.04.001.
  21. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014 May;60(5):940–7. doi: 10.1016/j.jhep.2013.12.019.
  22. Wong VW, Tse CH, Lam TT, Wong GL, Chim AM, Chu WC, Yeung DK, Law PT, Kwan HS, Yu J, Sung JJ, Chan HL. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis – a longitudinal study. PLoS One. 2013 Apr 25;8(4): e62885. doi: 10.1371/journal.pone.0062885
  23. Teterina L. A., Chikhacheva E. A., Seliverstov P. V., Sitkin S. I., Radchenko V. G. Rol’ mikroflory tolstoi kishki v razvitii latentnoi pechenochnoi entsefalopatii. Lechashchii vrach. 2012;(9):73–78. [In Russian]
  24. Seliverstov P. V., Prikhod’ko E.M., Sitkin S. I., Radchenko V. G., Vakhitov T. Ia., Shavarda A. L. Rol’ narushenii mikrobiotsenoza kishechnika i ekzometabolitov mikrobioty v razvitii nealkogol’noi zhirovoi bolezni pecheni. Gastroenterologiia Sankt-Peterburga. 2016;(3–4): M21–M22. [In Russian]
  25. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014 May;59(5):1738–49. doi: 10.1002/hep.26695.
  26. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015 Feb 3;5:8096. doi: 10.1038/srep08096.
  27. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016 Mar;63(3):764–75. doi: 10.1002/hep.28356.
  28. Fialho A, Fialho A, Thota P, McCullough AJ, Shen B. Small Intestinal Bacterial Overgrowth Is Associated with Non-Alcoholic Fatty Liver Disease. J Gastrointestin Liver Dis. 2016 Jun;25(2):159–65. doi: 10.15403/jgld.2014.1121.252.iwg.
  29. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig Dis Sci. 2012 Feb;57(2):545–53. doi: 10.1007/s10620–011–1887–4.
  30. World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics’. 2017 Feb. Available at: http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english [Accessed 18 January 2018].
  31. Maevskaia E. A., Maev I. V., Kucheriavyi Iu.A., Cheremushkin S. V., Andreev D. N. Otsenka vliianiia laktulozy ili pishchevykh volokon na dinamiku pokazatelei lipidnogo profilia u patsientov s funktsional’nym zaporom i nealkogol’nym steatogepatitom. Lechashchii vrach. 2016;(4):117–124. [In Russian]
  32. Sitkin S. I. Pishchevye volokna v klinicheskoi praktike. Freiburg, St. Petersburg, Dr. Falk Pharma GmbH, 2009. [In Russian]
  33. Radchenko V. G., Safronenkova I. G., Seliverstov P. V., Sitkin S. I. Pishchevye volokna v klinicheskoi praktike. Klinicheskie perspektivy gastroenterologii, gepatologii. 2010;(1):20–27. [In Russian]
  34. Anderson JW, Jones AE, Riddell-Mason S. Ten different dietary fibers have significantly different effects on serum and liver lipids of cholesterol-fed rats. J Nutr. 1994 Jan;124(1):78–83.
  35. Akbarzadeh Z., Nourian M., Askari G., Maracy M. R. The effect of Psyllium on body composition measurements and liver enzymes in overweight or obese adults with nonalcoholic fatty liver disease (NAFLD). Int J Adv Biotechnol Res. 2016 Apr;7(Spec Iss 3):1545–1554.
  36. Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis. PLoS One. 2013 May 16;8(5): e63388. doi: 10.1371/journal.pone.0063388.
  37. Jin CJ, Sellmann C, Engstler AJ, Ziegenhardt D, Bergheim I. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). Br J Nutr. 2015 Dec 14;114(11):1745–55. doi: 10.1017/S0007114515003621.
  38. Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, Liu C, Chen YW, Fan JG. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol. 2017 Jan 7;23(1):60–75. doi: 10.3748/wjg.v23.i1.60.
  39. Cresci GA, Glueck B, McMullen MR, Xin W, Allende D, Nagy LE. Prophylactic tributyrin treatment mitigates chronic-binge ethanol-induced intestinal barrier and liver injury. J Gastroenterol Hepatol. 2017 Sep;32(9):1587–1597. doi: 10.1111/jgh.13731.
  40. Cobbold JFL, Atkinson S, Marchesi JR, Smith A, Wai SN, Stove J, Shojaee-Moradie F, Jackson N, Umpleby AM, Fitzpatrick J, Thomas EL, Bell JD, Holmes E, Taylor-Robinson SD, Goldin RD, Yee MS, Anstee QM, Thursz MR. Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study. Hepatol Res. 2018 Jan;48(1):69–77. doi: 10.1111/hepr.12904.
  41. Terciolo C, Dobric A, Ouaissi M, Siret C, Breuzard G, Silvy F, Marchiori B, Germain S, Bonier R, Hama A, Owens R, Lombardo D, Rigot V, André F. Saccharomyces boulardii CNCM I-745 Restores intestinal Barrier Integrity by Regulation of E-cadherin Recycling. J Crohns Colitis. 2017 Aug 1;11(8):999–1010. doi: 10.1093/ecco-jcc/jjx030.
  42. Moré MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clin Exp Gastroenterol. 2015 Aug 14;11:237–55. doi: 10.2147/CEG.S85574.
  43. Liu YT, Li YQ, Wang YZ. Protective effect of Saccharomyces boulardii against intestinal mucosal barrier injury in rats with nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 2016 Dec 20;24(12):921–926. doi: 10.3760/cma.j.issn.1007–3418.2016.12.009.
  44. Li M, Zhu L, Xie A, Yuan J. Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation. 2015 Feb;38(1):170–9. doi: 10.1007/s10753–014–0019–7.
  45. Liu C, Song Y, McTeague M, Vu AW, Wexler H, Finegold SM. Rapid identification of the species of the Bacteroides fragilis group by multiplex PCR assays using group- and species-specific primers. FEMS Microbiol Lett. 2003 May 16;222(1):9–16. doi: 10.1016/S0378–1097(03)00296–9.
  46. Rinttilä T., Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol. 2004;97(6):1166–77. doi: 10.1111/j.1365–2672.2004.02409.x.
  47. Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006 Aug;118(2):511–21. doi: 10.1542/peds.2005–2824.
  48. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B, Stelma F, Adams H, van Ree R, Stobberingh EE. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007 May;56(5):661–7. doi: 10.1136/gut.2006.100164.
  49. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009 Aug;15(8):1183–9. doi: 10.1002/ibd.20903.
  50. Grzhibovskii A. M. Odnomernyi analiz povtornykh izmerenii. Ekologiia cheloveka. 2008;(4):51–60. [In Russian]
  51. Sitkin S. I., Vakhitov T. Ya., Tkachenko E. I., Oreshko L. S., Zhigalova T. N., Radchenko V. G., Seliverstov P. V., Avalueva E. B., Suvorova M. A., Komlichenko E. V. Gut microbiota in ulcerative colitis and celiac disease. Eksp Klin Gastroenterol. 2017;(1):8–30. [In Russian]
  52. Sakamoto M, Benno Y. Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen. nov., comb. nov., Parabacteroides goldsteinii comb. nov. and Parabacteroides merdae comb. nov. Int J Syst Evol Microbiol. 2006 Jul;56(Pt 7):1599–605. doi: 10.1099/ijs.0.64192–0.
  53. Nakanishi H, Shojo H, Ohmori T, Hara M, Takada A, Adachi N, Saito K. Identification of feces by detection of Bacteroides genes. Forensic Sci Int Genet. 2013 Jan;7(1):176–9. doi: 10.1016/j.fsigen.2012.09.006.
  54. Hong PY, Wu JH, Liu WT. Relative abundance of Bacteroides spp. in stools and wastewaters as determined by hierarchical oligonucleotide primer extension. Appl Environ Microbiol. 2008 May;74(9):2882–93. doi: 10.1128/AEM.02568–07.
  55. Kabiri L, Alum A, Rock C, McLain JE, Abbaszadegan M. Isolation of Bacteroides from fish and human fecal samples for identification of unique molecular markers. Can J Microbiol. 2013 Dec;59(12):771–7. doi: 10.1139/cjm-2013–0518.
  56. Tkachenko E. I. Nutrition, human endoecology, health, diseases. Current views on their relations. Ter Arkh. 2004;76(2):67–71. [Article in Russian]
  57. Vakhitov T. Ia., Sitkin S. I. The superorganism concept in biology and medicine. Eksp Klin Gastroenterol. 2014;(7):72–85. [Article in Russian]
  58. Heinken A, Sahoo S, Fleming RM, Thiele I. Systems-level characterization of a host-microbe metabolic symbiosis in the mammalian gut. Gut Microbes. 2013 Jan-Feb;4(1):28–40. doi: 10.4161/gmic.22370.
  59. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13780–5. doi: 10.1073/pnas.0706625104.
  60. Troy EB, Kasper DL. Beneficial effects of Bacteroides fragilis polysaccharides on the immune system. Front Biosci (Landmark Ed). 2010 Jan 1;15:25–34
  61. Narimani T, Douraghi M, Owlia P, Rastegar A, Esghaei M, Nasr B, Talebi M. Heterogeneity in resistant fecal Bacteroides fragilis group collected from healthy people. Microb Pathog. 2016 Jun;95:1–6. doi: 10.1016/j.micpath.2016.02.017.
  62. Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007 Oct;20(4):593–621. doi: 10.1128/CMR.00008–07.
  63. Xie G, Wang X, Liu P, Wei R, Chen W, Rajani C, Hernandez BY, Alegado R, Dong B, Li D, Jia W. Distinctly altered gut microbiota in the progression of liver disease. Oncotarget. 2016 Apr 12;7(15):19355–66. doi: 10.18632/oncotarget.8466.
  64. Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017 May;33(3):128–133. doi: 10.1097/MOG.0000000000000349.
  65. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013 Feb;57(2):601–9. doi: 10.1002/hep.26093.
  66. Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L, Chen Y, Li L. Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep. 2016 Aug 23;6:32002. doi: 10.1038/srep32002.
  67. Xue L, He J, Gao N, Lu X, Li M, Wu X, Liu Z, Jin Y, Liu J, Xu J, Geng Y. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep. 2017 Mar 28;7:45176. doi: 10.1038/srep45176.
  68. Cortez-Pinto H, Borralho P, Machado J, Lopes MT, Gato IV, Santos AM, Guerreiro AS. Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH). GE Port J Gastroenterol. 2016 Mar 31;23(3):132–141. doi: 10.1016/j.jpge.2016.01.004.
  69. Engstler AJ, Aumiller T, Degen C, Dürr M, Weiss E, Maier IB, Schattenberg JM, Jin CJ, Sellmann C, Bergheim I. Insulin resistance alters hepatic ethanol metabolism: studies in mice and children with non-alcoholic fatty liver disease. Gut. 2016 Sep;65(9):1564–71. doi: 10.1136/gutjnl-2014–308379.
  70. Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, Reo NV. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015 Feb;91(2):1–9. doi: 10.1093/femsec/fiu002.
  71. Akil I, Yilmaz O, Kurutepe S, Degerli K, Kavukcu S. Influence of oral intake of Saccharomyces boulardii on Escherichia coli in enteric flora. Pediatr Nephrol. 2006 Jun;21(6):807–10. doi: 10.1007/s00467–006–0088–4
  72. Patent 2595827 Russian Federation. Sposob prognozirovaniia effektivnosti provedeniia gepatotropnoi terapii u bol’nykh nealkogol’noi zhirovoi bolezn’iu pecheni. Khurtsilava O. G., Prikhod’ko E.M., Seliverstov P. V., Radchenko V. G., Sitkin S. I., Smolianinov A. B., Adylov Sh.F., Iurkevich Iu. V. Nr. 2015121975/15, 08.06.2015, opubl. 27.08.2016. Bulletin Nr. 24.
  73. Radchenko V. G., Seliverstov P. V., Ivanova V. F., Sitkin S. I. Algorithm of treatment of non-alcoholic fatty liver disease and the role of mitochondrial dysfunction in its development. Farmateka. 2017;(6):12–19. [In Russian]
Full text is published :
SACCHAROMYCES BOULARDII MODULATES THE COMPOSITION OF THE GUT MICROBIOTA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE, THUS PREVENTING THE PROGRESSION OF THE DISEASE. Experimental and Clinical Gastroenterology Journal. 2018;150(02):04-18
Read & Download full text

10.Title page: OPTIMIZATION OF THE MONITORING OF CONCENTRATIONS OF EVEROLIMUS IN PATIENTS AFTER HEART TRANSPLANTATION ON THE BACKGROUND OF LIVER PATHOLOGY
Bezvulyak E.I.¹, Melnichenikova O.S.¹, Vavilova T.V.¹, Simonenko M.A.², Sazonova Y.V.³, Fedotov P.A.⁴
1. Department of clinical laboratory diagnostics and genetics (St. Petersburg, Russian Federation)
2. Research laboratory of Cardiorespiratory testing (St. Petersburg, Russian Federation)
3. Research laboratory of thoracic surgery (St. Petersburg, Russian Federation)
4. Research laboratory of Figh–tech treatment (St. Petersburg, Russian Federation)
Abstract:Materials and methods of research. To study the effect of liver pathology on the pharmacokinetics of everolimus, the concentration of the drug in whole blood was determined by HPLC-MS/MS in 16 patients (men - 10, women - 6) after heart transplantation, observed in the fgbi “NMITS im. V. A. Almazova“ of the Ministry of health of the Russian Federation in the period 2016-2017, aged from 25 to 67 years (average age - 55.5 years). The average time after heart transplantation is 4.5 years. Patients received everolimus at a dose of 1.25 mg / day to 5.4 mg/day (average dose of everolimus - 2.5 mg / day).). In accordance with the distribution of nafr symptoms, the patients were divided into 2 groups (table.1): 1-4 patients with signs of nonalcoholic fatty liver disease (NAFLD), group 2 without evidence of NAFLD. The proposed method implemented using the method of high performance liquid chromatography combined with tandem mass spectrometry is straightforward, reproducible, rapid and reliable for the determination of everolimus in human whole blood with the aim of pharmacokinetic studies. Non-alcoholic fatty liver disease in patients after heart transplantation, receiving immunosuppressive therapy inhibitor mTOR everolimus, significantly affects the pharmacokinetics of the drug, achieving the target values, which can worsen the disease prognosis and quality of life.
- References total 11 ⇓ :: .
  1. Khalilulin TR, Garmash IV, Malaya IP, 2012. Clinico-pharmacological studies in patients with impaired liver function. Journal of Clinical pharmacology and therapy, 21 (2): 30–33.
  2. All-Russian public organization of transplantologists, "Russian Transplant Society", 2012. National clinical recommendations "Heart transplantation". www.transpl.ru.
  3. Lazebnik LB, Radchenko VG, Golovanova EV, Seliverstov PV and others, 2012. Non-alcoholic fatty liver disease: a clinic, diagnosis, treatment (recommendations for therapists, 2nd version). www.nogr.org.
  4. S. G. Zubova, J. V. Shitikova, Т. V. Pospelov, 2012. TOR – the centric concept of regulation of mitogenic, metabolic and energy signaling pathways in a cell. Cytology, 54 (8).
  5. M.I. Volkova, D. A. Nosov, V. A. Chernyaev et al., 2016. Efficacy and safety of everolimus in patients with advanced renal cell carcinoma (the results of a Russian multicenter observational study). Oncourology, 12: 18–27.
  6. A. N. Esaulenko, 2008. Therapeutic drug monitoring. Clinical and laboratory consultation, 3 (22): 6–10.
  7. Hallvard Holdaas, Paolo De Simone, Andreas Zuckermann, 2016. Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. Journal of Transplantation: 4369574, 11 pages.
  8. Jerome Dumortier, Sebastian Dharancy, Yvon Calmus, 2016. Use of everolimus in liver transplantation: The French experience. Transplantation Reviews, 30: 161–170.
  9. O.N. Reznik, A. N. Ananiev, I. V. Ulyankin, 2010. Early appointment of everolimus for kidney transplantation from donors with extended criteria. Bulletin of transplantology and artificial organs, 12: 19–26.
  10. Clinical recommendations: drug monitoring and interchangeability of original and generic immunosuppressants with a narrow therapeutic index, 2014. www.transpl.ru.
  11. N. V. Apanasenko, P. V. Kudan, F. S. Baranova, V. Yu., V. Yu. Abramov, 2013. Determination of the concentration of cyclosporin A in the blood by liquid chromatography mass spectrometry. // Clinical laboratory diagnostics, 6: 10–13.
Full text is published :
OPTIMIZATION OF THE MONITORING OF CONCENTRATIONS OF EVEROLIMUS IN PATIENTS AFTER HEART TRANSPLANTATION ON THE BACKGROUND OF LIVER PATHOLOGY. Experimental and Clinical Gastroenterology Journal. 2018;150(02):68-73
Read & Download full text

11.Title page: ANALIS LONG-TERM RESULTS OF MINIMALLY INVASIVE SURGICAL TREATMENT OF PATIENTS WITH CHOLECYSTOCHOLANGIOLITHIASIS
Degovtsov E.N.¹, Trukhan D.I. ¹ 📧 . Propp A.R.², Kolyadko P.V.³, Nikulina S.A.²
1. Omsk State Medical University of the Ministry of Health of Russia (Omsk, Russian Federation)
2. Regional Clinical Hospital (Omsk, Russian Federation)
3. Nizhnevartovsk District Clinical Hospital (Nizhnevartovsk, Russian Federation)
Keywords:cholecystocholangiolithiasis,minimally invasive surgery,fibrocholangioscopy,postoperative period,quality of life,ursodeoxycholic acid (UDCA)

Abstract:In the study, two groups of patients were compared: 31 patients operated with a single-step minimally invasive surgical method and 28 patients who were operated with a two-stage surgical procedure. To study the long-term results of treatment in patients with cholecystocholangiolithiasis who underwent surgical treatment, a questionnaire survey (questionnaire SF-36) and a survey including clinical (complaints, examination), laboratory tests (blood and urine test, bilirubin level, ALAT, ACAT, AF) and instrumental (ultrasound, fibrogastroduodenoscopy) research methods. The obtained results of the conducted study testify to the undoubted advantage of one-stage minimally invasive surgical treatment of patients with cholecystocholangiolithiasis. Quality of life indicators in patients taking UDCA drugs at the postoperative stage of smoking were better in comparison with patients who did not take UDCA, which may serve as an additional reason for prescribing UDCA drugs after cholecystectomy. The received results of the conducted research testify to an undoubted advantage of one-stage minimally invasive surgical treatment of patients with cholecystocholangiolithiasis.
- References total 39 ⇓ :: .
  1. Lazebnik L. B., Kopaneva M. I., Ezhova T. B. Sravnitel’noe issledovanie kachestva zhizni u bol’nykh zhelchnokamennoi bolezn’yu i postkholetsistektomicheskim sindromom. Materialy 5-go Slavyano-Baltiiskogo nauchnogo foruma. Sankt-Peterburg. Gastro, 2003; 2–3:93.
  2. Lazebnik L. B., Kopaneva, I.M., Ezhova T. B. Need for medical care after surgery on the stomach and gall bladder (Review of references and own observations). Terapevtichesky Arkhiv, 2004, 2: 83–87.
  3. Minushkin O. N. Syndrome after cholecystectomy in the practice of the therapist and the gastroenterologist. Lechaschy Vrach, 2015, 2: 40–47.
  4. Minushkin O. N., Guseva L. V., Burdina E. G. i dr. Bol’nye posle udaleniya zhelchnogo puzyrya. Vsegda li eto postkholetsistektomicheskii sindrom? Medical Advice. 2016;14: 122–8.
  5. Vinokurov M. M., Pavlov I. A., Gogolev N. M. i dr. Khirurgicheskoe lechenie bol’nykh ostrym kal’kuleznym kholetsistitom, oslozhnennym kholedokholitiazom i mekhanicheskoi zheltukhoi. Annaly khirurgicheskoi gepatologii. 2004;2:114–5.
  6. Collins C., Maguire D., Ireland A. A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann. Surg. 2004;1: 28–33.
  7. Vetshev P. S., Chilingaridi K. E., Ippolitov L. I. et al. Life quality of patients after various methods of cholecystectomy. Annaly khirurgicheskoi gepatologii,. 2003; 8 (1): 72–79. – (In Russ.)
  8. Beburishvili A. G., Bykov A. V., Zyubina E. N., Burchuladze N. Sh. Evolyutsiya podkhodov k khirurgicheskomu lecheniyu oslozhnennogo kholetsistita. Khirurgiya. Zhurnal im. N. I. Pirogova. 2005;1: 43–7.
  9. Bystrovskaya E. V., Il’chenko A. A. Otdalennye rezul’taty kholetsistektomii. Eksperimental’naya i klinicheskaya gastroenterologiya. 2008; 5: 23–7.
  10. Aliev Yu. G., Kurbanov F. S., Popovich V. K. et al. Maloinvazivnoe khirurgicheskoe lechenie ostrogo i oslozhnennogo kal’kuleznogo kholetsistita. Moscow Surgical Journal. 2014; 2: 35–8.
  11. Franks, P., Lubetkin, E., Gold, M. R. et al. Mapping the SF-12 to the EuroQol EQ-5D Index in a National US Sample. Medical Decision Making. 2004. 24(3), 247–254. doi: 10.1177/0272989X04265477.
  12. Brazier J., Roberts J. & Deverill M. The Estimation of a Preference-based Measure of Health from the SF-36. Journal of Health Economics. 2004. 21(2), 271–292
  13. Novik A. A. Issledovanie kachestva zhizni v meditsine: ucheb. posobie. M., GEOTAR-MED. 2004. P. 304
  14. Quintana J. M., Cabriada J., Arostegui I. et al. Quality-of-life outcomes with laparoscopic vs open cholecystectomy Surg. Endocs. 2003;17:1129–34.
  15. Cherkasov M. F., Kuzmenko V. L. Possibility of forecasting cholecystectomy long-term results. Modern problems of science and education. 2016;3: 178–87
  16. Savchenko Y. P., Bensman V. M., Karipidi G. K., Gumenyuk S. E., Suzdaltsev I. V. Long-term results of surgical treatment of cholecystitis, depending on the method of cholecystectomy Kuban Scientific Medical Bulletin 2016;5: 98–101
  17. Trukhan D. I. Rational pharmacotherapy in gastroenterology. Spravochnik poliklinicheskogo vracha. 2012; 10: 18–24. (In Russ.)
  18. Trukhan D. I., Filimonov S. N., Tarasova L. V. Klinika, diagnostika i lechenie osnovnykh zabolevanii zhelchnogo puzyrya i zhelchevyvodyashchikh putei. Novokuznetsk: OOO.Poligrafist., 2013. p. 111
  19. Trukhan D. I., Filimonov S. N., Tarasova L. V. Klinika, diagnostika i lechenie osnovnykh zabolevanii zhelchnogo puzyrya i zhelchevyvodyashchikh putei. Novokuznetsk: OOO.Poligrafist., 2013. p.154
  20. Trukhan D. I., Tarasova L. V. Drug safety and rational drug therapy in gastroenterologic practice. Klinicheskiye Perspektivy Gastroenterologii, Gepatologii, 2013, 5: 9–16.
  21. Tarasova L. V., Trukhan D. Idrug safety in gastroenterology. Eksperimental’naya i klinicheskaya gastroenterologiya 2013; 4: 81–7.
  22. Trukhan D. I. Vybor lekarstvennogo preparata s pozitsii ratsional’noi farmakoterapii. Consilium Medicum. 2013; 11: 45–9.
  23. Trukhan D. I. Originaly i generiki: perezagruzka v svete ekonomicheskogo krizisa. Spravochnik poliklinicheskogo vracha. 2012;4: 32–6.
  24. Kazyulin A. N. Place of ursodeoxycholic acid in the therapy of non-alcoholic fatty liver disease at different stages: steatosis, steatohepatitis, fibrosis / cirrhosis. RMJ. 2017. № 17. P. 1248–1257.
  25. Kazyulin A. N., Goncharenko A. Yu., Kalyagin I. E. Application of ursodezoxycolic acid for prevention and treatment of cholelithiasis in the practice of the first contact physicians. RMJ. MEDICAL REVIEW. 2017. № 2. P. 80–87.
  26. E. V. Esaulenko, O. E. Nikitina, N. V. Dunaeva, A. N. Uskov, T. L. Mogilevets. Clinical experience with ursodeoxycholic acid (Urdoxa) in complex therapy of chronic viral hepatitis. Journal Infectology 2011; 3: 42–5. (In Russ.)
  27. Sologub T. V., Osinovets O. Y. Experience of application of Urdox drug in patients of chronic hepatitis in the cirrhosis stage. Terra Medica, 2012, 2: 9–17. (In Russ.)
  28. Baranovskii A. Yu., Raikhel’son K. L., Semenov N. V., Solonitsyn E. G. Principles of cholestatic liver diseases treatment. Lechashchii vrach. 2012; 7: 43–9. (In Russ.)
  29. Zinovieva E. N., Mekhtiev S. N., Mekhtieva O. A. Modern aspects of pathogenetic therapy of non-alcoholic fatty liver disease. Effective Pharmacotherapy. Gastroenterology. 2012;26: 24–9. (In Russ.)
  30. Veselova E. N., Alekseev E. E., Mkrtchyan L. S. Place ursodeoxycholic acid in modern hepatology. Medical bulletin of the South Russia. 2012; 1: 36–9.
  31. Avalueva EB, Tkachenko EI, Skazyevaeva EV et al. Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome. Experimental and clinical gastroenterology/ Eksp Klin Gastroenterol. 2013; 11: 26–30. (In Russ.)
  32. Zubritsky V. F., Gibadulin N. V., Kostyuchenko M. V. Рrevention of post-operation hepatorenal syndrome. Effective Pharmacotherapy. Gastroenterology. 2013; 1: 42–8. (In Russ.)
  33. L. N. Kostyuchenko. Nutritional support for postcolectomy syndrome: what’s new? Effective Pharmacotherapy. Gastroenterology. 2013; 3 (31): 10–4 (In Russ.)
  34. Trukhan D. I., Viktorova I. A. Gallbladder disease and biliary tract in practice doctor first contact: passive waiting or active surveillance. Medical Advice. 2016; 14:109–15 DOI: http://dx.doi.org/10.21518/2079–701X-2016–14–109–115
  35. Myazin R. G. The role of ursodeoxycholic acid in the treatment of chronic viral hepatitis. Medical Advice. 2017;4: 31–5. DOI: http://dx.doi.org/10.21518/2079–701X-2017–4–31–35
  36. Pimanov S. I., Makarenko Е. V. Idiosyncratic drug-induced liver injury: diagnosis and treatment. Medical Advice. 2017; 5:100–7. (In Russ.)
  37. Tsukanov V. V., Tonkikh Yu. L., Vasyutin A. V. Recommendations for management of patients with functional disorders of the gall bladder and sphincter of Oddi. Medical advice. 2017; 11: 100–3. (In Russ.)
  38. Shul’pekova Yu. O., Shul’pekova N. V., Semenistaya M. Ch. Clinical and pathogenetic substantiation of the use of ursodeoxycholic acid in the treatment of cholelithiasis. Russian Medical Journal. 2017; 10: 745–9. (In Russ.)
  39. Kazyulin A. Place of ursodeoxycholic acid in the therapy of non-alcoholic fatty liver disease at different stages of the disease: steatosis, steatohepatitis, fibrosis / cirrhosis. MEDICAL ALPHABET. 2017; 40: 50–60 (In Russ.)
Full text is published :
ANALIS LONG-TERM RESULTS OF MINIMALLY INVASIVE SURGICAL TREATMENT OF PATIENTS WITH CHOLECYSTOCHOLANGIOLITHIASIS. Experimental and Clinical Gastroenterology Journal. 2018;150(02):74-81
Read & Download full text

12.Title page: THE STATE OF HEMOSTASIS SYSTEM IN RATS WITH TOXIC HEPATITIS UNDER THE CONDITIONS OF ALIMENTARY DEPRIVATION OF PROTEIN
Voloshchuk O.N. ¹ 📧 . , Kopylchuk G. P.¹
1. Institute of Biology, Chemistry and Bioresources of Chernovtsi national university named by Yurii Fedkovych, Biochemistry and biotechnology department (Chernivtsi, Ukraine)
Keywords:acetaminophen-induced hepatitis,alimentary deprivation of protein,indicators of hemostasis system

Abstract:The hemostasis system indicators of rats with acetaminophen-induced hepatitis under the conditions of alimentary deprivation of protein were assessed in the research. Research was conducted on 4 groups of animals: 1 - control; 2 - rats maintained on low-protein diet; 3 - rats with acute acetaminophen-induced hepatitis, maintained on full-value ration, 4 - rats with acute acetaminophen-induced hepatitis, maintained under the conditions of alimentary deprivation of protein. The activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT) and fibrinogen concentration were determined by optical method on a semi-automated coagulometer HUMACLOT Junior (Human GmbH, Germany). The content of soluble fibrin-monomer complexes (SFMC) was assessed using the “RFMK test” test system; the serum D-dimer concentration was determined by enzyme immunoassay. Our study established an increase of prothrombin time in protein-deficient animals, while in other parameters of the hemostasis system significant changes were not detected. Meanwhile, a significant increase of APTT, prothrombin and thrombin time is established in animals with acetaminophen-induced hepatitis. At the same time, the results of this study suggest that the accumulation of blood fibrinogen and SFMC is higher in almost 3 and 1.5 times respectively compared to control values, on the background of maintaining of the D-dimer concentration at the control level. The most pronounced changes of hemostatic system are observed in animals with toxic liver damage, which contained on a low protein diet. A decrease of procoagulant blood potential was established in rats of this group that was shown by increase of APTT, prothrombin time and also of hyperfibrinogenemia on the background of the accumulation of SFMC. In conclusion, acetaminophen-induced liver damage is accompanied by disorders of the hemostasis system, which are most pronounced in protein-deficient animals. The established elongation of APTT, PT, TT and the increasing of fibrinogen and SFMC contents indicate the formation of the hypocoagulation state and risk of hemorrhage. The results of the research can be used for biochemically substantiate and the development of optimal strategy for the correction of coagulopathies as consequences of toxic liver damage..
- References total 19 ⇓ :: .
  1. Potze W., Porte R. J., Lisman Т. Management of coagulation Abnormalities in liver disease // Expert Review of Gastroenterology & Hepatology. - 2015. - Vol. 9, № 1. - Р. 103-114.
  2. Tripathi G.K., Katara A. A., Awasthi S. V., Srivastava S. V. Correlation of coagulation profile in liver disease patients in a tertiary care hospital // Int J Cur Res Rev. - 2016. - Vol. 8, № 8. - P. 1-3.
  3. Schadena E., Sanerb F. H., Goerlinger K. Coagulation pattern in critical liver dysfunction // Curr Opin Crit Care. -2013. - Vol. 19. - P. 19:00-0000 DOI:10.1097/MCC.0b013e32835ebb52.
  4. Lisman Т., Kwaan H. C. Hemostatic Dysfunction in Liver Diseases // Semin Thromb Hemost. - 2015. - Vol. 41, № 5. - Р. 445-446.
  5. Lisman Т., Caldwell S. H., Burroughs А. К. et al. Hemostasis and thrombosis in patients with liver disease: The ups and downs // Journal of Hepatology. - 2010. - Vol. 53. - P. 362-371.
  6. Andriulli A., Tripodi A., Angeli P. et al. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference // Digestive and Liver Disease. - 2016. - Vol. 48. - P. 455-467.
  7. Northup P.G., Caldwell S. H. Coagulation in Liver Disease: A Guide for the Clinician // Сlinical gastroenterology and hepatology. - 2013. - Vol. 11. - Р. 1064-1074.
  8. Lisman T., Porte R. J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences // Blood. - 2010. - Vol. 116. - P. 878-885.
  9. Voloshchuk O. N., Kopylchuk G. P., Badyak O. D. Activity Of The Liver Malate-Aspartate Shuttle Mitochondrial Enzymes In Rats Under The Conditions Of Alimentary Deficiency Of Protein. Fundamental medicine and biology. 2014;83 (3). p. 12–16.
  10. Voloshchuk O.N., Kopylchuk G. P. The Peculiarities of the Structural and Functional State of the Cytochrome Component of the Liver Mitochondrial Respiratory Chain under Conditions of Acetaminophen-Induced Hepatitis on the Background of Alimentary Protein Deprivation // Biophysics. - 2015. - Vol. 60, № 3. - Р. 420-424.
  11. Devrajani B.R., Talpur M. A.A., Atta-ur-Rahman A. et al. Coagulopathies in Patients with Liver Cirrhosis // World Applied Sciences Journal. - 2012. - Vol. 17, № (1). - P. 01-04.
  12. Tripodi A., Caldwell S. H., Hoffman M. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease // Aliment Pharmacol Ther. - 2007. - Vol. 26. - P. 141-148.
  13. Shah S.N., Trupti J. Coagulation profile in liver disease-a study of 100 cases // Gujarat medical journal. - 2014. - Vol. 69, № 1. - P. 37-40.
  14. Kopylchuk G. P., Voloshchuk O. N. Modeling of the acetaminophen-induced disturbances of the bile producing liver function under the conditions of alimentary deprivation of protein. Biomedicine. 2015;№2. p. 30–36.
  15. Voloshchuk O.N., Kopyl’chuk G.P., Buchkovskaia I. M. Activity of the marker liver enzymes under the conditions of toxic hepatitis and alimentary deprivation of protein // Experimental & clinical gastroenterology. - 2014. - Vol. 108, № 8. - P. 96-100.
  16. Sajaa M.F., Abdob A. A., Sana F. M. et al. The coagulopathy of liver disease: does vitamin K help? // Blood Coagulation and Fibrinolysis. - 2013. - Vol. 24, № 1. - P. 10-17.
  17. Groeneveld D.J., Adelmeijer J., Hugenholtz G. C.G. et al. Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation // Journal of Thrombosis and Haemostasis. - 2015. - Vol. 13. - P. 2192-2201.
  18. Tennent G.A., Brennan S. O., Stangou A. J. et al. Human plasma fibrinogen is synthesized in the liver // Blood. - 2007. - Vol. 109, № 5. - P. 1971-1974.
  19. Tripodi A. D-Dimer Testing in Laboratory Practice // Clinical Chemistry. - 2011. - Vol. 57, № 9. - P. 1256-1262.
Full text is published :
THE STATE OF HEMOSTASIS SYSTEM IN RATS WITH TOXIC HEPATITIS UNDER THE CONDITIONS OF ALIMENTARY DEPRIVATION OF PROTEIN. Experimental and Clinical Gastroenterology Journal. 2018;150(02):82-88
Read & Download full text

13.Title page: LIVER DISEASE IN CHILDREN CAUSED BY Α1-ANTITRYPSIN DEFICIENCY
Vlasov N.N. ¹ 📧 . , Kornilenko E.A.¹, Melnik S.I.^2,3
1. St. Petersburg State Pediatric Medical University (St. Petersburg, Russian Federation)
2. Saint-Petersburg State Research Institute of Phthisiopulmonology (St. Petersburg, Russian Federation)
3. North-Western State Medical University n. a. I. I. Mechnikov (St. Petersburg, Russian Federation)
Keywords:α₁-antitrypsin deficiency,liver damage with α₁-antitrypsin deficiency,liver disease in children

Abstract:Alpha-1 antitrypsin deficiency is a frequent metabolic, genetically-associated disease in which the liver is affected, primarily in patients with a ZZ phenotype. However, according to the literature to 20 years of life, only 10-15% of patients retain or develop clinical signs of the disease. We observed 7 children with the ZZ phenotype of α₁-antitrypsin, who had a severe neonatal cholestasis, a neonatal liver syndrome, and asymptomatic moderate hyperfermentemia in young children at the initial examination. In the course of further follow-up, a tendency toward weakening of the manifestations of the disease or normalization of liver laboratory tests was observed in all, no one showed signs of progression of liver fibrosis for a period of up to 3 years. However, in children among genetic diseases in this disease, most often there is a need for a liver transplant. Diagnosis of α₁-antitrypsin deficiency is to determine its level in the blood and phenotyping. Genetic diagnosis is possible. Treatment of liver damage with α₁-AT deficiency is an unresolved problem, but in recent years new strategies have been applied when it is possible to influence individual pathological mechanisms that cause liver damage.
- References total 52 ⇓ :: .
  1. Perlmutter D. H.: “Alpha-1-antitrypsin” // In book Schiff E. R., Sorrell M. F., Maddrey W. C. (eds.) Schiff’s Diseases of the Liver, 11th edn. Oxford, Wiley-Blackwell, 2011, p. 835-867.
  2. Silverman E. K., Sandhaus R. A.: “Clinical practice. Alpha1-antitrypsin deficience” // N. Engl. J. Med., 2009, 360, p. 2749-2757.
  3. Sherlock S., Dooley J.: «Diseases of the Liver and Biliary System» // Oxford, UK: Blackwell Science Ltd a Blackwell Publishing, 11 Edition, 2002-706 p.
  4. Teckman J. H., Qu D., Perlmutter D. H.: “Molecular pathogenesis of liver disease in α₁-antitrypsin deficiency” // Hepatology, 1996, 24, p. 1504-1516.
  5. Carlson J. A., Rogers B. B., Sifers R. N. et al.”Accumulation of PiZ antitrypsin causes liver damage in transgenic mice” // Clin. Invest. 1988, 83, p. 1183-1190.
  6. Eriksson S.: “α₁-antitrypsin deficiency” // J. Hepatol., 1999, 30, suppl. 1, p. 34-39.
  7. Perlmutter D. H.: “Alpha-1-antitrypsin deficiency” // Semin. Liver Dis., 1998, 18, p. 217-222.
  8. Crystal R. G.: “α₁-Antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy” // J. Clin. Invest, 1990, 85, p. 1343-1352.
  9. Lomas D. A.: Loop sheet polymerization: the structural basis of Z α₁-antitrypsin accumulation in the liver” // Clin. Sci., 1994, 86, p. 489.
  10. Lomas D. A., Evans D. L.I., Finch J. T. et al.: “The mechanism of Z α₁-antitrypsin accumulation in the liver” // Nature, 1992, 357, p. 605-607.
  11. Qu D., Teckman J. H., Perlmutter D. H.: “α₁-Antitrypsin deficiency associated liver disease” // J. Gasroenterol., Hepatol., 1997, 12, p. 404-416.
  12. Teckman J. H., Perlmutter D. H.: “Conceptual advances in the pathogenesis and treatment of childhood liver disease” // Gasroenterology, 1995, 108, p. 1263-1279.
  13. Wu G., Whitman F., Mobments E. et al.: “A lag in intracellular degradation of mutant α₁-antitrypsin correlated with the liver disease phenotype in homozygous PiZZ α₁-antitrypsin deficiency” // Proc. Natl. Acad. Sci. USA, 1995, 91, p. 9014-9018.
  14. Geller S., Hichols W. S., Dycacio M. J. et al.; ‘Histopathology of α₁-antitrypsin liver disease in a transgenic mouse model” // Hepatology, 1990, 12, 40, p. 40-47.
  15. Geller S., Hichols W. S., Kim S. S. et al.; “Hepatocarcinogenesis is the sequel to hepatitis in Z#2 α₁-antotrypsin transgenic mice: histopatholgical and DNA ploidy studies” // Hepatology, 1994, 19, p. 389-397.
  16. Perlmutter D. H.: “Alpha-1-antitrypsin deficiency: Importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates” // Annu Rev. Med., 2011, 62, 4.1-4.13.
  17. Hadzic N., Quaglia A., Mieli-Vergani G.: “Hepatocellular carcinoma in a 12-year-old child with PiZZ α₁-antitrypsin deficiency” // Hepatology, 2006, 43, p. 194.
  18. Zhou H., Ortiz-Pallardo M.E., Ko Y., Fischer H-P.: “Is heterozygous alpha-1-antitrypsin deficiency type PiZ a risk factor for primary liver cancer” // Cancer, 2000, 88, p. 2668-2676.
  19. Perlmutter D.: “α₁-Antitrypsin deficiency” // In book Suchy F. J., Sokol R. J., Balistreri W. F. Liver Disease in Children. Fourth Edition. Cambridge University Press 2014, p. 400-418.
  20. Propst T., Propst A., Dietze O. et al.: “Prevalence of hepatocellular carcinoma in α₁-antitrypsin deficiency” // J. Hepatol., 1994, 21, p. 1006.
  21. Glasgow J. F.T., Lynch, Hercz A. et al.: “α₁-antitrypsin deficiency in association with both cirrhosis and chronic obstructive lung disease in two sibs” // Am. J. Med., 1973, 54, p. 181.
  22. Bakula A., Socha P., Adamowich M. et al.: “Early and late clinical presentation of α-1 antitrypcin deficiency in children” // Gut, 2005, suppl. N VII, vol. 54 - Endoscopy, 2005, suppl. N1, vol. 34, p. A 193.
  23. Francavilla R., Castellaneta S. P., Hadzic N. et al.: “α-1 antitrypsin deficiency: a 29 years experience in 241 children”. // J. Hepatol., 1999, vol. 30, suppl. № 1, p. 51.
  24. Francavilla R., Castellaneta S. P., Hadzic N. et al.: “Prognosis of alpha-1-antitrypsin deficiency-related liver disease in the era of paediatric liver transplantation”. // J. Hepatol., 2000, 32, р. 986-989.
  25. Sveger T., Eriksson S.: “The liver in adolescents with α₁-anritrypsin deficiency” // Hepatology, 1995, 22, р. 514-517.
  26. Roberts E. A.: “ The Acutely Ill Baby” // In book “Diseases of the Liver and Biliary System in Children Edited By Deirdre Kelly, 2008, Blackwell Publishing, p. 57-105.
  27. Nord K. S., Saad S., Joshi V.V, Mc Loughlin L.C.: “Concurrence of a1-antitrypsin deficiency and biliary atresia” // J. Pediatr., 1987, 111, p. 416-418.
  28. Cottrall K., Cook P. J.L., Mowat A. P.: “Neonatal hepatitis syndrome and alpha-1-antitrypsin deficiency: An epidemiological study in south-east England” // Postgrad. Med. J., 1974, 50, p. 376-380.
  29. Roberts E. A.: “The Jaundiced Baby” // In book: Kelly D.: Diseases of the Liver and Biliary System in Children. Third Edition. Blackwell Publishing, 2008, p. 57-106.
  30. Sharp H. I.: “Alpha 1-antitrypsin deficiency” // Hosp. Pract., 1971, 6(5), p. 83-96.
  31. Sveger T.: “The natural history of liver disease in α₁-antitrypsin deficient children” // Acta Paediatr. Scand., 1988, p. 847-851.
  32. Ybarguen E., Gross C. R., Savik S. K. et al.: “Liver disease in α₁-antitrypsin deficiency: prognostic indicators” // J. Pediatr., 1990, 117, p. 864-870.
  33. Sveger T.: “Liver disease in α₁-antitrypsin deficiency detected by screening of 200 000 infants” // N. Engl. J. Med., 1976, 294, 1216-1221.
  34. Brantly M.: “Laboratory diagnosis of α₁-АТ deficiency”. // In Crystal R. G. editor. Alpha 1-Antitrypsin Deficiency: Biology, Pathogenesis, Clinical Manifestations, Therapy. New York: Marcel Dekker, 1996, p. 221-226.
  35. Pitulainen E., Carlson J., Ohlsson K. et al.: “Alpha-1-antitrypsin deficiency in 26-year-old subjects: lung, liver and protease/protease inhibitor studies” // Chest 2005, 128, 2076-2081.
  36. Volpert D, Molleston J.P, Perlmutter D.H. Alpha1-antitrypsin deficiency-associated liver disease progresses slowly in some children. // J. Pediatr. Gastroenterol. Nutr., 2000б 31б, р. 258-263.
  37. Graziadi I. W., Joseph J. J., Wiesner R. H. et al: “Increased risk of chronic liver failure in adults with heterozygous α₁-antitrypsin deficiency” // Hepatology, 1998, 28, p. 1058.
  38. Pittschieler K.: “Heterozygotes and liver involvement”. // Acta Paediatr., 1994, 83 (suppl. 393), p. 21-23.
  39. Francavilla R., Castellaneta S. P., Hadzic N. et al.: “Liver disease in PiSS/PiSZ phenotype of α-1 antitrypsin deficiency”. // J. Hepatol., 1999, vol. 30, suppl. № 1, p. 164.
  40. Psacharopoulos H. T., Mowat A. P., Cook P. J. et al.: “Outcome of liver disease associated with alpha 1 antitrypsin deficiency (PiZ). Implications for genetic counselling and antenatal diagnosis” // Arch. Dis. Child., 1983, 58, p. 882-887.
  41. Nebbia G., Hadchouel M., Odievre M. et al.: “Early assessment of evolution of liver disease associated with alpha 1-antitrypsin deficiency in childhood” // J. Pediatr., 1983, 102, p. 661-665.
  42. Ibarguen E, Gross C.R, Savik S.K, Sharp H.L. Liver disease in alpha-1-antitrypsin deficiency: prognostic indicators. // J. Pediatr., 1990, 117, 864-870.
  43. Prachalias A. A., Kalife M., Francavilla R. et al.: “Liver transplantation for alpha-1-antitrypsin deficiency in children” // Transpl. Int., 2000, 13, 207-210.
  44. Teckman J. H., Perlmutter D. H.: “Retention of mutant α₁-antitrypsin Z in endoplasmatic reticulum is associated with an autophagic response” // Am. J. Physiol., 2000, 279, G961-G974.
  45. Lang T., Mühlbauer M., Strobelt M. et al.: “Alpha-1-antitrypsin deficiency in children: liver disease is not reflected by low serum levels of alpha-1-antitrypsin a study on 48 pediatric patients” // Eur. J. Med. Res., 2005, 10, p. 509-514.
  46. Teckman J. H.: “Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: preliminary study” // J. Pediatr. Gastroenterol. Nutr., 2004, 39, 34-37.
  47. Burrows J. A., Willis L. K., Perlmutter D. H.: “Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: a potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency” // Proc. Natl. Acad. Sci. U S A 2000, 97, 1796-1801.
  48. Marcus N. Y., Perlmutter D. H.: “Glucosidase and mannosidase inhibitor mediate increased secretion of mutant α₁-antitrypsin Z” // Z. J. Biol. Chem., 2000, 275, 1987-1992.
  49. Hidvegi T., Ewing M., Hale P. Et al.: “An autophagy-enhancing drug promotes degradation of mutant α1-antitrypsin Z and reduces hepatic fibrosis” // Science, 2010, 329, p. 229-232.
  50. Kemmer N., Kaiser T., Zacharias V. et al.: “Alpha-1-antitrypsin deficiency: outcomes after liver transplantation” // Transplant. Proc., 2008, 40, 1492-1494.
  51. Vennarecci G., Gunson B. K., Ismail T. et al.: “Transplantation for end stage liver disease related to alpha 1 antitrypsin” // Transplantation, 1996, 61, p. 1488-1495.
  52. Van Furth r., Kramps J. A., van der Putten A. B. et al.: “Change in alpha-1-antitrypsin phenotype after orthotopic liver transplant” // Clin. Exp. Immunol., 1986, 66, p. 669.).
Full text is published :
LIVER DISEASE IN CHILDREN CAUSED BY Α1-ANTITRYPSIN DEFICIENCY. Experimental and Clinical Gastroenterology Journal. 2018;150(02):89-99
Read & Download full text

14.Title page: MODERN VIEWS ON NUTRITION AND PHYSICAL ACTIVITY IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
Gubergrits N.V. ¹ 📧 . , Byelyayeva N.V.¹, Klochkov A.Y.¹, Lukashevish G.M.¹, Fomenko P.G.¹
1. Donetsk National Medical University (Donetsk, Ukraine)
Keywords:non-alcoholic fatty liver disease,non-alcoholic steatohepatitis,treatment,diet,physical activity

Abstract:The article presents literature data of recent years on the relevance of the problem of non-alcoholic fatty liver disease. The data on the role of physical activity, decrease in body weight upon this pathology are analyzed. Peculiar attention is paid to nutrition recommendations with variants of hypocaloric diets. An algorithm for changing lifestyle, increasing physical activity and dietary nutrition is presented, aimed at reducing body weight and treating non-alcoholic fatty liver disease.
- References total 48 ⇓ :: .
  1. Ivashkin V. Т. Clinical variants of metabolic syndrome / V. Т. Ivashkin, О. М. Drapkina, О. N. Кorneeva. – Мoscow: Меd. Inform. Agency, 2011. – 220 p.
  2. Overweight and obesity: consequences for health and life, modern guidelines on reaching and keeping the normal body mass / V. G. Perederiy, S. М. Тkach, V. I. Кutovoy, М. М. Rotter. – Kiev: Start-98, 2013. – 240 p.
  3. Tkach S. M. Modern pharmacotherapy of non-alcoholic fatty liver disease/ S. М. Тkach, Т. Y. Yuzvenko, Т. L. Cheverda // Health of Ukraine. – 2017. – No 18. – P. 68–71.
  4. Shvets О. V. Dietary recommendations for patients with disseminated compensated liver diseases / О. V. Shvets // Health of Ukraine. – 2016. – No 8. – P. 3.
  5. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort / V. W. Setiawan, L. R. Wilkens, S. C. Lu [et al.] // Gastroenterology. - 2015. - Vol. 148. - P. 118-125.
  6. Barb D. Pharmacological management of nonalcoholic fatty liver disease / D. Barb, P. Portillo-Sanchez, K. Cusi // Metabolism. - 2016. - Vol. 65. - P. 1183-1195.
  7. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach / S. Bellentani, R. Dalle Grave, A. Suppini [et al.] // Hepatol. - 2008. - Vol. 47. - P. 746-754.
  8. Bird’s eye view of nonalcoholic fatty liver disease - an insulin resistant state / T. P. Manopriya, A. Elshaari Faraj, S. Dhastagir, A. Sheriff // Acta Medica Saliniana. - 2010. - Vol. 39, No 1. - P. 1-5.
  9. Coffee and herbal tea consumption is associated with lower liver stiffness in the general population: the Rotterdam study / L. J. M. Alferink, J. Fittipaldi, J. C. Kiefte-de Jong [et al.] // J. Hepatol. - 2017. - Vol. 67, No 2. - P. 339-348.
  10. Coffee drinking and alcoholic and nonalcoholic fatty liver diseases and viral hepatitis in the multiethnic cohort / V. W. Setiawan, J. Porcel, P. Wei [et al.] // Clin. Gastroenterol. Hepatol. - 2017. - Vol. 15, No 8. - P. 1305-1307.
  11. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis / F. Bravi, C. Bosetti, A. Tavani [et al.] // Clin. Gastroenterol. Hepatol. - 2013. - Vol. 11. - P. 1413-1421.
  12. Development of new fatty liver, or resolution of existing fatty liver, over 5 year of follow up: effect of exercise / K.-S. Sung, S. Ryu, J.-Y. Lee [et al.] // J. Hepatol. - 2016. - Vol. 65. - P. 791-797.
  13. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology / N. Chalasani, Z. Younossi, J. E. Lavine [et al.] // Gastroenterology. - 2012. - Vol. 142, No 7. - P. 1592-1609.
  14. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease / G. Marchesini, C. P. Day, J.-F. Dufour [et al.] // J. Hepatol. - 2016. - Vol. 64, No 6. - P. 1388-1402.
  15. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis / L. Loffredo, M. Del Ben, L. Perri [et al.] // Aliment. Pharmacol. Ther. - 2016. - Vol. 44, No 3. - P. 279-286.
  16. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial / M. Razavi Zade, M. H. Telkabadi, F. Bahmani [et al.] // Liver Int. - 2016. - Vol. 36, No 4. - P. 563-571.
  17. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group / F. M. Sacks, L. P. Svetkey, W. M. Vollmer [et al.] // N. Engl. J. Med. - 2001. - Vol. 344. - P. 3.
  18. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis / S. Watanabe, E. Hashimoto, K. Ikejima [et al.] // J. Gastroenterol. - 2015. - Vol. 50, No 4. - P. 364-377.
  19. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis / S. Keating, D. Hackett, J. George, N. Johnson // J. Hepatol. - 2012. - Vol. 57. - P. 157-166.
  20. Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression / L. A. Orci, K. Gariani, G. Oldani [et al.] // Clin. Gastroenterol. Hepatol. - 2016. - Vol. 14, No 10. - P. 1398-1411.
  21. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013 / M. Ng, T. Fleming, M. Robinson [et al.] // Lancet. - 2014. - Vol. 384, No 9945. - P. 766-781.
  22. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels / P. Portillo-Sanchez, F. M. Bril, M. Maximos [et al.] // J. Clin. Endocrinol. Metab. - 2015. - Vol. 100. - P. 2231-2238.
  23. A highsucrose isocaloric pair-fed model induces obesity and impairs NDUFB6 gene function in rat adipose tissue / A. Lomba, F. I. Milagro, D. F. Garcia-Diaz [et al.] // J. Nutrigenet. Nutrigenomics. - 2009. - Vol. 2. - P. 267-272.
  24. Inadequate dietary magnesium intake increases atherosclerotic plaque development in rabbits / J. L. King, R. J. Miller, J. P. Blue Jr. [et al.] // Nutr. Res. - 2009. - Vol. 29. - Vol. 343-349.
  25. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis / Y. Yang, D. Zhang, N. Feng [et al.] // Gastroenterology. - 2014. - Vol. 147. - P. 1031-1042.
  26. Insulin sensitivity increase after calcium supplementation and change in intraplatelet calcium and sodium-hydrogen exchange in hypertensive patients with type 2 diabetes / M. I. Pikilidou, A. N. Lasaridis, P. A. Sarafidis [et al.] // Diabet. Med. - 2009. - Vol. 26. - P. 211-219.
  27. Keating S. E. Exercize in NAFLD: just do it / S. E. Keating, L. A. Adams // J. Hepatol. - 2016. - Vol. 65. - P. 671-673.
  28. Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabetic patients / L. Bozzetto, A. Prinster, G. Annuzzi [et al.] // Diabetes Care. - 2012. - Vol. 35. - P. 1429-1435.
  29. Loomba R. The global NAFLD epidemic / R. Loomba, A. J. Sanyal // Nat. Rev. Gastroenterol. Hepatol. - 2013. - Vol. 10, No 11. - P. 686-690.
  30. Mediterranean diet and hepatocellular carcinoma / F. Turati, D. Trichopoulos, J. Polesel [et al.] // J. Hepatol. - 2014. - Vol. 60. - P. 606-611.
  31. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with nonalcoholic fatty liver disease / M. C. Ryan, C. Itsiopoulos, T. Thodis [et al.] // J. Hepatol. - 2013. - Vol. 59, No 1. - P. 138-143.
  32. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study / C. P. Wen, J. P. Wai, M. K. Tsai [et al.] // Lancet. - 2011. - Vol. 378. - P. 1244-1253.
  33. Non-alcoholic fatty liver disease is not associated with a lower health perception / L. Mlynarsky, D. Schlesinger, R. Lotan [et al.] // World J. Gastroenterol. - 2016. - Vol. 22. - P. 4362-4372.
  34. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States / R. J. Wong, M. Aguilar, R. Cheung [et al.] // Gastroenterology. - 2015. - Vol. 148, No 3. - P. 547-555.
  35. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men / J. M. Chan, E. B. Rimm, G. A. Colditz [et al.] // Diabetes Care. - 1994. - Vol. 17, No 9. - P. 961-969.
  36. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial / S. A. Harrison, W. Fecht, E. M. Brunt, B. A. Neuschwander-Tetri // Hepatology. - 2009. - Vol. 49, No 1. - P. 80-86.
  37. The possible role of Ca2+ on the activation of microsomal triglyceride transfer protein in rat hepatocytes / H. J. Cho, H. C. Kang, S. A. Choi [et al.] // Biol. Pharm. Bull. - 2005. - Vol. 28. - P. 1418-1423.
  38. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study / E. M. Koehler, E. P. Plompen, J. N. Schouten [et al.] // Hepatology. - 2016. - Vol. 63, No 1. - P. 138-147.
  39. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients / G. Targher, L. Bertolini, R. Padovani [et al.] // Diabetes Care. - 2007. - Vol. 30. - P. 1212-1218.
  40. Prevention of diabetes with Mediterranean diets: a subgroup analysis of a randomized trial / J. Salas-Salvado, M. Bullo, R. Estruch [et al.] // Ann. Intern. Med. - 2014. - Vol. 160, No 1. - P. 1-10.
  41. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease / S. Ryu, Y. Chang, H. S. Jung [et al.] // J. Hepatol. - 2015. - Vol. 63. - P. 1229-1237.
  42. Rinella M. E. Nonalcoholic fatty liver disease: a systematic review / M. E. Rinella // JAMA. - 2015. - Vol. 313. - P. 2263-2273.
  43. Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty liver disease / P. Y. Portillo, S. Yavuz, F. Bril, K. Cusi // Curr. Hepatol. Rep. - 2014. - Vol. 13. - P. 159-170.
  44. Unwin N. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action / N. Unwin, D. Gan, D. Whiting // Diabetes. - Res. Clin. Pract. - 2010. - Vol. 87, No l. - P. 2-3.
  45. Weight gain as a risk factor for clinical diabetes mellitus in women / G. A. Colditz, W. C. Willett, A. Rotnitzky [et al.] // Ann. Intern. Med. - 1995. - Vol. 122, No 7. - P. 481-486.
  46. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis / E. Vilar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot [et al.] // Gastroenterology. - 2015. - Vol. 149, No 2. - P. 367-378.
  47. World Health Organization (WHO), Fact Sheet No 311 (updated March 2013) //www.who.int/mediacentre/factsheets/fs311/en/
  48. Zelber-Sagi S. Evidence for lifestyle and weight management for the progression of NAFLD, metabolic or cardiovascular disease / S. Zelber-Sagi. - EASL postgraduate course: non-alcoholic fatty liver disease. - The Netherlands (Amsterdam), 2017. - P. 49-56.
Full text is published :
MODERN VIEWS ON NUTRITION AND PHYSICAL ACTIVITY IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE. Experimental and Clinical Gastroenterology Journal. 2018;150(02):100-109
Read & Download full text

15.Title page: CHOLECISTOCARDIAC SYNDROME: TROUBLES OF DIFFERENTIAL DIAGNOSIS
Oganezova I.A. ^1,2 📧 . , Egorova S.V.², Skvortsova T.E.¹, Medvedeva O.I.¹
1. Public budgetary educational institution of higher education “North-western State Medical University named after I. I. Mechnikov” of the Ministry of Healthcare of the Russia (St. Petersburg, Russian Federation)
2. Health Сare Unit of State Unitary Enterprise “Vodokanal of St. Petersburg” (St. Petersburg, Russian Federation)
Keywords:cholelithiasis,cholecystocardial syndrome,cholecystectomy

Abstract:The article presents data on the prevalence, clinical manifestations of cholelithiasis. The connection between the pathology of the biliary tract and changes in the activity of the cardiovascular system was noted. A clinical picture of cholecystocardial syndrome (CCS) and tactics of disease management with this pathology are described. The case of own clinical observation of a patient with CCS illustrates the published literature data.
- References total 14 ⇓ :: .
  1. Popova IR, Pavlov Ch. S., Glushchenkov DV, Drapkyna OM, Ivashkin VT The prevalence of the liver disease and gallbladder disorders in patients with body weight and obesity. Klinicheskaya Medicina [Clinical Medicine] 2012; 90 (10):38–43 (in Russian)
  2. Stinton L. M., Shaff er E. A. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver, 2012; 6 (2): 172–87.
  3. Radchenko VG, Shabrov A. V., Zinovieva E. N., Sinkin S. I. Zabolevaniya pecheni i zhelchevyvodyashchikh putey: rukovodstvo dlya vrachey [Diseases of the liver and bile ducts: a guide for doctors]. SPb: SpetsLit, 2011. 526 p. ISBN978–5–299–00348–2 (in Russian)
  4. Recommendations of the Russian gastroenterological association for the diagnosis and treatment of gallstone disease. RZHGGK, 2016; 3: 64–80 (in Russian)
  5. Skvortsova TE, Sitkin SI, Radchenko VG, Seliverstov PV, Tkachenko EI Zhelchnokamennaya bolezn'. Sovremennyye podkhody k diagnostike, lecheniyu i profilaktike: posobiye dlya vrachey [Gallstone disease. Modern approaches to diagnosis, treatment and prevention: a manual for doctors]. Moscow: Forte print, 2013. 32 p. (in Russian)
  6. Kazyulin AN Masks of biliary dysfunction. Eksperimental'naya i klinicheskaya gastroenterologiya [Experimental and clinical gastroenterology] 2015; 114 (2): 71–81 (in Russian)
  7. Gubergrits NB, Lukashevich GM Zhelchnokamennaya bolezn': ot S. P. Botkina k sovremennosti [Gallstone disease: from SP Botkin to the present]. Moscow: 4TE Art, 2011. 48 p (in Russian)
  8. Vetshev PS, Nogtev PV Cholecystokardial syndrome – a myth or reality. Khirurgiya. Zhurn. im. N. I. Pirogova [Surgery. Jour. them. NI Pirogov] 2005; 3: 59–64 (in Russian)
  9. Trukhan DI, Tarasova LV, Bagisheva NV Pain in the thorax associated with diseases of the digestive system Dnevnik Kazanskoy meditsinskoy shkoly [Diary of the Kazan Medical School] 2014;4: 49–53 (in Russian)
  10. Gridnev AE Cholecystocardial syndrome. [Electronic resource] Access mode: / URL: http: // health-ua.com/articles/1518.
  11. Kazyulin A. N. Pain syndrome in diseases of the biliary tract Meditsinskiy vestnik [Medical Bulletin] 2012; 17–18: 17 (in Russian)
  12. D. I. Trukhan. Differential diagnosis of pain in the chest: in focus – diseases of the digestive system Consilium Medicum. 2015; 1: 63–67 (in Russian)
  13. Styazhkina SN, Sayfullina AR, Zagidulina SI Diagnosis of acute cholecystitis. Differential Diagnosis of Cholecystocardial Syndrome Sinergiya nauk [Synergy of Sciences] 2017; 10: 823–827 (in Russian)
  14. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. Journal of Hepatology, 2016. Juli; Vol. 65 (1): 146–181.
Full text is published :
CHOLECISTOCARDIAC SYNDROME: TROUBLES OF DIFFERENTIAL DIAGNOSIS. Experimental and Clinical Gastroenterology Journal. 2018;150(02):110-114
Read & Download full text

16.Title page: DISEASE AND CAROLI’S SYNDROME: CURRENT STATE OF THE PROBLEM
Skvortsov V.V. ¹ 📧 . , Levitan B.N², Lunkov M.V.¹, Morozov A.V.¹
1. Volgograd State Medical University (Volgograd, Russian Federation)
2. Astrakhan State Medical University (Astrakhan, Russian Federation)
Keywords:Caroli’s disease, cholangiocarcinoma, hepatectomy, Caroli’s syndrome, polycystic kidney disease, bile ducts, abdominal pain, cholangitis, liver transplantation, endoscopic retrograde cholangiopancreatography

Abstract:This review focuses on the clinical picture, approaches to diagnosis and therapy of Caroli’s disease and Caroli’s syndrome.
- References total 27 ⇓ :: .
  1. Mabrut JY, Kianmanesh R, Nuzzo G, Castaing D, Boudjema K, Létoublon C, et al. Surgical management of congenital intrahepatic bile duct dilatation, Caroli’s disease and syndrome: longterm results of the French Association of Surgery Multicentre Study. Ann Surg. 2013; 258:713–721.
  2. Zhong-Xia Wang, Yong-Gang Li, Rui-Lin Wang, et al. Clinical classification of Caroli’s disease: an analysis of 30 patients. HPB (Oxford). 2015 Mar; 17(3): 278–283.
  3. Man Mohan Harjai, RK Bal, SK Mohantyet al. Caroli Disease And Caroli Syndrome. Med J Armed Forces India. 2017 Apr; 55(2): 155–156.
  4. Min Hye Jang, Yoon Jin Lee, and Haeryoung Kim. Intrahepaticcholangiocarcinoma arising in Caroli’s disease. Clin Mol Hepatol. 2014 Dec; 20(4): 402–405.
  5. Ko JS, Yi NJ, Suh KS, Seo JK. Pediatric liver transplantation for fibropolycystic liver disease. Pediatr Transplant. 2012; 16:195–200.
  6. Sato Y, Ren XS, Nakanuma Y. Caroli’s disease: current knowledge of its biliary pathogenesis obtained from an orthologous rat model. Int J Hepatol. 2012; 2012:107945.
  7. Dae Hoe Gu, Min Seon Park, Chang Ho Jung. Caroli’s disease misdiagnosed as intraductal papillary neoplasm of the bile duct. Clin Mol Hepatol. 2015 Jun; 21(2): 175–179.
  8. Zhang DY, Ji ZF, Shen XZ, Liu HY, Pan BJ, Dong L. Caroli’s disease: a report of 14 patients and review of the literature. J Dig Dis. 2012; 13:491–495.
  9. Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012; 54:580–587.
  10. Eiko Hasegawa, Naoki Sawa, Junichi Hoshino. Recurrent Cholangitis in a Patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Caroli’s Disease. Intern Med. 2016 Oct 15; 55(20): 3009–3012.
  11. Suwabe T, Ubara Y, Sumida K, et al. Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria. ClinExpNephrol 16: 892–902, 2012.
  12. Bergmann C. ARPKD and manifestations of ADPKD: the original polycystic kidney disease and phenocopies. Pediatr Nephrol 30: 15–30, 2015.
  13. Harring TR, Nguyen NT, Liu H, Goss JA, O’Mahoney CA. Caroli disease patients have excellent survival after liver transplant. J Surg Res 177: 365–372, 2012.
  14. Monitoring Editor: Alexander Muacevic and John R Adler. Caroli’s Disease as a Cause of Chronic Epigastric Abdominal Pain: Two Case Reports and a Brief Review of the Literature. Cureus. 2017 Sep; 9(9): e1701.
  15. Yonem O, Bayraktar Y. Clinical characteristics of Caroli’s Clinical characteristics of Caroli’s syndrome. World J Gastroenterol 2007; 13(13): 1934–1937.
  16. Ros E., Navarro S., Bru C., et al. Ursodeoxycholic acid treatment of primary hepatolithiasis in Caroli’s syndrome. Lancet 1993, 342:404–406.
  17. Cabral Correia P, Morgado B. Caroli’s Disease as a Cause of Chronic Epigastric Abdominal Pain: Two Case Reports and a Brief Review of the Literature. September 20, 2017. Cureus 9(9): e1701.
  18. Tsunoda T, Furui J, Yamada M, et al. Caroli’s disease associated with hepatolithiasis: a case report and review of the Japanese literature. Gastroenterol Jpn 1991, 26:74–79.
  19. Caroli’s disease: radiologic spectrum with pathologic correlation. Levy AD, Rohrmann CA Jr, Murakata LA, Lonergan GJ AJR Am J Roentgenol. 2002 Oct; 179(4):1053–7.
  20. Kassahun WT, Kahn T, Wittekind C, et al. Caroli’s disease: liver resection and liver transplantation. Experiencein 33 patients. Surgery. 2005, 138:888–898.
  21. Morozov D. A., Gusev A. A., Pimenova E. S. Bile Duct Cysts: Modern Aspects of Surgical Treatment and Clinical Observationof a Rare Case. Voprosy sovremennoi pediatrii – Current Pediatrics. 2015; 14 (3): 412–415.
  22. Levitan B. N., Umerova A. R., Larina N. N. Chronicheskaya patologiya pecheni I kishechnii microbiocenoz (kliniko-patogeneticheskie aspekty). Astrahan´, 2010, 135 s.
  23. Levitan B. N., Sal´nikova G.G., Umerova A. R. Klinicheskaya effektivnost´ plazmafereza pri sindromah endogennoi intoksikacii i vnutripechenochnogo holestaza pri hronicheskih diffuznih zabolevaniyah pecheni // Astrahanskii medicinskii zhurnal. 2003. T.4. N4. S.6–11.
  24. Ivashkin V. T., Shirokova E. N., Maevskaya M. V. Klinicheskie rekomendacii Rossiiskoi gastroenterologicheskoi associacii i Rossiiskogo obshestva po izucheniyu pecheni po diagnostike i lecheniyu cholestaza // Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2015. T.25. N2. S.41–57.
  25. Vnutrennie bolezni / V. V. Skvortsov. – Moskva: Eksmo, 2010. – 1077 s.
  26. Skvortsov V. V., Tumarenko A. V. Klinicheskaya gastroenterologiya: kratkii kurs / V. V. Skvortsov, A. V. Tumarenko. – Sankt-Peterburg: Speclit, 2015. – 183 s.
  27. Kozlova I. V., Pahomova A. L. Prakticheskaya gastroenterologiya. Rukovodstvo dlya vrachei: uchebnoye posobie dlya sistemi poslevuzovskogo professional´nogo obrazovaniya vrachei / I. V. Kozlova, A. L. Pahomova. Moskva: Drofa, 2010. Tom 2. 345 s.
Full text is published :
DISEASE AND CAROLI’S SYNDROME: CURRENT STATE OF THE PROBLEM. Experimental and Clinical Gastroenterology Journal. 2018;150(02):115-120
Read & Download full text

23.Title page: ASSESSMENT OF CHANGES IN BIOCHEMICAL BLOOD PARAMETERS IN A PATIENT DIAGNOSED WITH LIVER CIRRHOSIS, USING AUTOLOGOUS MESENCHYMAL STEM CELLS
Kotkas I.E. ¹ 📧 . , Asadulayev Sh.M.¹, Marchenko N.V.¹, Enukashvili N.I.¹
1. North-western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
2. Children’s Scientific Clinical Center of Infectious Diseases of Federal Medical Biological Agency (St. Petersburg, Russian Federation)
3. Pokrovsky Bank of Stem Cells (St. Petersburg, Russian Federation)
4. Institute of Cytology RAS (St. Petersburg, Russian Federation)
Keywords:liver cirrhosis,cell therapy,autologous mesenchymal stem cells,imaging cells in the human body

Abstract:The article provides our own observation of the use of autologous mesenchymal stem cells for the treatment of a patient with cirrhosis of the liver. In this observation, the possibility of visualization in the human body of the introduced autologous mesenchymal stem cells is presented. Changes in biochemical blood parameters are also presented one month after the introduction of cellular structures into the arterial bed of the liver.
- References total 6 ⇓ :: .
  1. Ludwig J., Viggiano T. R. Non–alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin Proc. 1980, 55:434–8.
  2. M. Carneiro de Moore. Nonalcoholic steatohepatitis // Clinical perspectives in gastroenterology, hepatology. – 2001. – № 2. – p. 12–15
  3. Fadeenko G. D. Fat liver: etiopathogenesis, diagnosis, treatment // Modern gastroenterology. 2003. – No. 3 (13). – pp. 9–17.
  4. Severov M. Non-alcoholic fatty liver disease / / Vrach. – 2002. – № 10. – p.23–26., 1212.
  5. Bellentani S, Tinbelli C. Epidemiology and risk factors for fatty liver. In: Leuschner U. James OFW, Dancygier H (eds.). Steatohepatitis (NASH and ASH), Kluwer Academic Publishers, Dordrecht 2001, 3–10.
  6. Kantarcıoğlu M, Demirci H, Avcu F, Karslıoğlu Y, Babayiğit MA, Karaman B, Öztürk K, Gürel H, Akdoğan Kayhan M, Kaçar S, Kubar A, Öksüzoğlu G, Ural AU, Bağcı S.: Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis. The Turkish J ournal of gastroenterology 2015 May;26(3):244–50.
Full text is published :
ASSESSMENT OF CHANGES IN BIOCHEMICAL BLOOD PARAMETERS IN A PATIENT DIAGNOSED WITH LIVER CIRRHOSIS, USING AUTOLOGOUS MESENCHYMAL STEM CELLS. Experimental and Clinical Gastroenterology Journal. 2018;150(02):174-176
Read & Download full text

24.Title page: SEVERE DRUG-INDUCED CHRONIC LIVER DISEASE IN 30-YEAR-OLD PATIENT
Grinevich V.B.¹, Kravchuk Yu.A.¹, Ped V.I.¹, Arapkhanova M.M. ¹ 📧 .
1. S. M. Kirov Military Medical Academy the Russian Defense Ministry (St. Petersburg, Russian Federation)
Keywords:Drug-induced chronic liver disease,Idiosyncrasy,Levofloxacin,Ursodeoxycholic acid

Abstract:The presented clinical observation reflects the key issues of the drug-induced chronic liver disease (DICLD): the complexity of the interpretation of the cause-and-effect relationship. The drug-liver, the severity of the flow, the diagnostic concept, as an exclusion method, the lack of treatment standards and the difficulty of finding an effective therapy.
- References total 16 ⇓ :: .
  1. Болезни печени и желчевыводящих путей: Руководство для врачей/ Под ред. В. Т. Ивашкина. – М.: ООО «Издат. дом «М-Вести», 2002. – 416 с.
  2. Внутренние болезни. Печень, желчевыводящие пути, поджелудочная железа: учебное пособие /Г.Е. Ройтберг, А. В. Струтынский. – М.: МЕДпресс-информ, 2013. – 632 с.
  3. S. F. Galimova. Drug-induced liver injuries (Part 2). RJGHC. 2014. Vol.24. No1. P.21–28.
  4. Лекарственные поражения печени. Клинические рекомендации для врачей / Санкт-Петербургское общество гастроэнтерологов, гепатологов и диетологов. Райхельсон К. Л., Пальгова Л. К., Кондрашина Э. А., Марченко Н. В., Барановский А. Ю. – СПб., 2017. – 116 с.
  5. Хомерики С. Г. Холестаз: учебное пособие для врачей/ С. Г. Хомерики, Н. М. Хомерики. – М.: Прима Принт, 2014. – 52 с.
  6. Циммерман Я. С. Синдром холестаза (вопросы этиологии, патогенеза, классификации, диагностики и лечения): учебно-методическое пособие для врачей. – Пермь, 2005. – 38 с.
  7. Шерлок Ш., Дули Дж. Заболевания печени желчных путей: Пер. с англ. / Под ред. З. Г. Апросиной, Н. А. Мухина. – М.: Гэотар-Медицина, 1999. – 864 с.
  8. Björnsson E. S. Hepatotoxicity by Drugs: The Most Common Implicated Agents // Int J Mol Sci. – 2016. – Vol. 6; 17(2). – Р. E224.
  9. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. //World J Gastroenterol. – 2008. – Vol. 14(44). – Р. 6774–6785.
  10. Chen M., Suzuki A., Borlak J. et al. Drug-induced liver injury: Interactions between drug properties and host factors. //Journal of Hepatology. – 2015 – Vol.63. – P. 503–514.
  11. Chalasani N.P., Hayashi P.H, Bonkovsky H.L et al. ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury // The American Journal of Gastroenterology. – 2014. –Vol. 109. –Р. 950–966.
  12. Rajesh K.G., Suzuki R., Maeda H. et al. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K. Akt dependent pathway // J. Mol. Cell. Cardiol. – 2005. – Vol. 39 (5). – P. 766–776.
  13. Stine J.G., Lewis J. H. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review // Expert Rev GastroenterolHepatol. – 2016. – Vol. 10(4). – P. 517–536.
  14. Karlsen T.H., Lammert F., Thompson R. J. Genetics of liver disease: From pathophysiology to clinical practice. // Journal of Hepatology. – 2015. –Vol.62. –S.6-S.14
  15. Zimmerman H. J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals ОП the Liver. – New York, 1978. – Р. 349–369.
  16. http://livertox.nlm.nih.gov
Full text is published :
SEVERE DRUG-INDUCED CHRONIC LIVER DISEASE IN 30-YEAR-OLD PATIENT. Experimental and Clinical Gastroenterology Journal. 2018;150(02):177-182
Read & Download full text

25.Title page: SOME MECHANISMS OF INTRAHEPATIC HEMODYNAMIC DISORDERS AND ITS CORRECTION IN CHRONIC LIVER DISEASES WITH AN INITIAL STAGE OF FIBROSIS
Ermolova T. V. ¹ 📧 . , Ermolov S.U.¹, Sologub T.V.¹, Karev V.E.¹, Dobkes A.L.¹
1. State Medical University named after I. I. Mechnikov of Russian Federation Ministry of Public Health (St. Petersburg, Russian Federation)
Keywords:chronic hepatitis,endothelial disfunction,portohepatic hemodynamics,hepatic stellate cells,polyhepatography,L-ornithine-L-aspartate

Abstract:We investigated 97 patients with chronic viral hepatitis В и C, 30- nonalcoholic and alcoholic steatohepatitis with liver fibrosis 0-1stage. For the estimation of liver microcirculation we used non-invasive method polyhepatography (modificated liver impedansometry). Activation of HSCs was determined by expression of SMA-alfa in liver bioptate. Endothelial function was estimated by peripheral arterial tonometry (EndoPAT-2000), by expression of eNOS, iNOS in liver bioptate (immunohystochemical reactions) and by determination of NO metabolits in blood. For correction of hepatic blood flow disorders we used L-ornithine-L-aspartate, test with nitrates and deep respiration. we revealed the disorders of intrahepatic microcirculation on presinusoidal level (in-flow) at the viral patients and on sinusoidal level (out-flow) at steatohepatitis with increase of basic resistance and decrease of blood filling of the liver. The endothelial disfunction was identified: disorders od endothelia-depended vasodilatation, increased NO metabolits in blood, presence of iNOS expression and moderate decreased eNOS in liver. In liver bioptate we revealed the signs of activation of HSCs - expression of SMA-alfa. L-ornithine-L-aspartate improved liver microcirculation in all patients. at the chronic liver diseases patients with fibrosis 0-1 we detected the hepatic microcirculation disorders in different levels in depending on the ethiology of the disease. Functional tests with nitrates confirmed functional character of this disorders in cases of fibrosis 0. Endothelial dysfunction and activation of HSCs are important pathogenetic factors of increased hepatic resistance. L-ornithine-L-aspartate can improve liver microcirculation.
- References total 55 ⇓ :: .
  1. Polunina Т. Е. Nonalcoholic fatty liver disease and metabolic syndrome.Gastroenterologia. 2012. № 2. P. 5–9. (in Russ)
  2. Mehtiev S.N., Kravchuk U. A., Mehtieva O. A. Portal Hypertension – modern understanding of problem. Hepatologicheski Forum. 2008. № 1. P. 11–15.(in Russ)
  3. Bulatova I. A., Schekotov V. V., Schekotova A. P. Functional status of endothelium at the hepatitis and liver cirrhosis. The markers of endothelial disfunction. – LAP LAMBERT Acad.Publ. 2011. (in Russ)
  4. Еrmolov S. U., Shabrov A. V., Dobkes A. L. Polihepatography. Hemodinamics. Hepatitis.-SPb.: ELBI-SPb. 2007. 324 p. (in Russ)
  5. Paciorа М. D. Surgery of portal hypertension. – M.: Мedicina.1974.498 p. (in Russ)
  6. McIndoe A. N. Vascular lesions in portal cirrhosis. Arch Path Lab Med .1928. no.5.P.23–42.
  7. Sanyal A., Shah V. Portal Hypertension. Pathology, Evaluation, and Treatment. – New Jersey. 2005. 505 p.
  8. Mehta G., Gustot T., Mookerjee R. P. et al. Inflammation and Portal hypertension – the undiscovered country. J.of Hepatology.2014. vol.61. P. 155–163.
  9. Shah V. Cellular and molecular basis of portal hypertension. Clin., Liver Dis.2001. 3. P. 629–644.
  10. Elbakidze G. М. The mechanizms of protective action of activated Kupphers cells by endotoxin on hepatocytes. Vestnik of Rossiyskoi Academii Medicinskih Nauk. 2012. № 5. P. 48–54. (in Russ)
  11. Bosch J., Abraldes JG., Garcia-Pagan JC. The clinical use of HVPG measurements in CLD. Nat Rev Gastroenterology Нepatology. 2009.no.6. P. 573–582.
  12. Borisov А.Е., Кuzmin-Кrutetski М.I., Каschenko V. А. et al. Bleedings of portal genesis: questions of the diagnostic and medical endoscopy.SPb. 2001. 128p.(in Russ)
  13. Pribilov S. А. The correction of endothelial disfunction and portal hypertension at the liver cirrhosis by beta-blockers and ICE-inhibitors. Vestnik novih medicinskih tehnologii. 2007.№ 10 (1). P. 51–53. (in Russ)
  14. Bosch J. Portal Hypertension.EASL monothematic conference “Portal hypertension” Budapest. Hungary. Jan. 22–24.2009. P. 5–7.
  15. Drapkinа О. М., Deevа Т. А., Ivashkin V. Т. The estimation of endothelial function and degree of apoptosis at the patients with metabolic syndrome and NAFLD. Тerap. Arhiv.2015. № 5. P. 75–83. (in Russ)
  16. Stoiko U. М., Litkin М. I., Shaidakov Е. V. Venous hypertension in the system of caval viens. SPb.: Rubin. 2002. 276 p. (in Russ)
  17. Parin V. V., Meerson F. Z. Essays of clinical physiology of blood circulation. 1965. 500 p. (in Russ)
  18. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic ceils of the liver. Physiol Rev. 2008. vol.88. no.1. P. 125–172.
  19. Schuppan D. Kim YO. Evolving therapies for liver fibrosis. J Clin Invest .2013.123. P. 1887–1901.
  20. Kawada N., Klein H., Decker К. Eicosanoid-mediated contractility of hepatic Stellate cells. Biochem J.1992. vol.285. P. 367–371.
  21. Reynaert H., Thompson MG., Thomas T. et al. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut, 2002.50. P. 571–581.
  22. Reynaert H., Urbain D., Ceerts A. Regulation of sinusoidal perfusion in portal hypertension. Anat Rec. 2008. vol.291. no.6. P. 693–698.
  23. Liu Z., Rossen Van E., Timmermans JP. et al. Distinct roles for non-muscle myosin II isoforms in mouse hepatic stellate cells. J Hepatol. 2011. vol.54. no.1.P.132–141. Epub 2010 Aug 26.
  24. Geerts V., Timmermans JP., Reynaert H. Hepatic circulation. Anat Rec (Hoboken).2008.vol.291. P. 611–613.
  25. Rockey D.C., Weisinger R. A. Endothelium induces contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology.1996. vol.24. P. 233–240.
  26. Jalan R., De Chiara F., Balasubramaniyan V. et al. Ammonia produces pathological changes in human hepatic stellate cells and is target for therapy of portal hypertension. J. of Hepatology. 2016. vol.64. no.4. P. 823–833.
  27. Bоgоmоlоv P.О., Bueverov А. О. et al. Hyperammoniemia at the patients with liver diseases at precirrhotic stage: is it possibly? (preliminary results of study “SMART RADAR”). Clinicheskie perspectivi Gastroenterologii, Hepatologii, 2013. № 5.P.3–9. (in Russ)
  28. Gorg B., Qvartskhava N., Keitel V. et al. Ammonia induces RNA oxidation in cultured astrocytes and brain in vivo. Hepatology .2008. vol.48. P. 567–579.
  29. Balasubramaniyan V., Wright G., Sharma V. et al. Ammonia reduction with ornithine phenylacetate restores brain eNOS acnvity via the DDAH-ADMA pathway in bile due ligated cirrhotic cars. Am J Physiol Gastrointest Liver Physiol. 2012. vol. 302. P. 145–152.
  30. Langer DA., Das A., Semela D.et al. No promotes caspase-independent HSC apoptosis through the gemeration of reactive oxygen species. J Hep.2008. vol.47. P. 1983–93.
  31. Rockey D.C., Chung J. Reduced NO production by endothelial cells in cirrhotic rat liver: endothelial disfunction in Portal hypertension. Gastroenterology. 1998. vol.114. P. 344–351.
  32. Pasarin M., Abraldes JG., Rodrigues-Vilarrupla A. et al. Insulin resistance and liver microcirculation in a rat model of early MS. J Hep. 2011. vol.55. P. 1095–1102.
  33. Levitan B. N. The relationship of portal pressure with nitric oxide level in plasma at the liver cirrhosis. Experimentanayal i clinicheskaya gastroenterologia. 2014. № 5 (105). p.65. (in Russ)
  34. Wei CL., Khoo HE., Lee KH., Hon WM. Differential expression and localization of NOSs in cirrhotic rats livers. Nitric oxide. 2002. no.7. P. 91–102.
  35. Wiest R., Groszman RJ. The paradox of NO in cirrhosis and portal hypertension: too much, not enough. J. Hep.2002. vol.35, P. 478–491.
  36. Bosch J., Abraldes JG., Garcia-Pagan JC. The clinical use of HVPG measurements in CLD. Nat Rev Gastroenterology Hepatology. 2009. no.6. P. 573–582.
  37. T.-Leung Т.М., Tipoe G. I., Liong Е. С. et al. e-NOS is an important factor at the experimental liver fibrosis. Int.J. of Exp.Pathology. 2008. vol.89. P. 241–250.
  38. Iwakiri J., Grisham M., Shah V. Vascular biology and pathology of liver: report of a single-topic symposium. Hepatology.2008. vol.47. P. 1754–1763.
  39. Chesnokova L.V., Petrov I. М., Sidorovа Е. А. et al. Liver fibrosis and endoteliaql function markers at the patients with metabolic syndrome. Rossiyskiy Zshurnal Gastroenterologii, Hepatologii and Coloproctologii. 2014. № 6. P. 45–50. (in Russ).
  40. Hon W. H., Lee W. H., Khoo H. E. Nitric oxide in liver diseases. Annals of the New York Academy of Sience., 2002. vol.962. P. 278–295.
  41. Pocrovsky V.I., Vinogradov N. A. Nitric oxide, its physiological and pathophysiological characteristics. Terap.Arhiv.2005. № 1.P. 82–87. (in Russ)
  42. Moncada S., Palmer R., Higgs E. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmac.Rev. 1991.vol.43. P. 109–142.
  43. Gardner C. R. Role of nitric oxide in hepatotoxocity // C. R. Gardner, S. K. Durham, D. Barton et al, Cells of Hepatic Sinusoid, The Netherlands: Kupffer Cells Foundation. 1997. vol. 6. P. 268–271.
  44. Zvenigorodskaya L.A., Nilovа Т. V. Nitric oxide is as marker of inflammation at the steatohepatitis patients with metabolic syndrome. Russiyskiy Medicinskiy Zshurnal. Zabolevaniya pischevaritelnih organov. 2008. № 2. P. 47–50. (in Russ)
  45. Vanin А. F. Nitric oxide – regulator of cellular metabolism. Sorosa Obrazovatelniy Zshurnal. 2001. № 1 (7). P. 7–12. (in Russ)
  46. Еrmolova Т.V., Еrmolov S. U., Shabrov A. V. et al. Endothelial disfunction and disorders of portohepatic hemodynamic at the chronic viral hepatitis patients/Petrischev N.N., Endothelialnaya disfunctsia. Patogeneticheskaya rol i metodi correctsii. SPb.: IIC, Voenno-medicinskaya akademiya.2007. 296 p. (in Russ)
  47. Ratnikova L. I., Melnikov I. V. The value of nitric oxide in damage of hepatocytes at liver pathology. Epidemiologia i infecionnie bolezni. 2002. № 6. P. 50–54. (in Russ)
  48. Langer DA., Shah VH. NO and Portal Hypertension: Interface of vasoreactivity and angiogenesis. J.of Hep.2006.v.44. P. 209–216.
  49. Abraldes J.G., Garcia-Pagan J.C., Rodriguez V. Simvastatin treatment improves liver sinusoidal endothelial disfunction in CCl4 cirrhotic rats. J. Hepatology. 2007. vol.46. P. 1040–1046.
  50. Ermolova T., Ermolov S., Dobkes A. et al. Non-invasive evaluation of intrahepatic blood flow at the chronic liver diseases patients. Abstracts of EASL monothematic conference “Portal hypertension” Budapest (Hungary). Jan. 22–24 2009. no.19.
  51. Severin Е. S. Biochemistry. – М.: GEOTAR-Med, 2003. (in Russ)
  52. Tkach S. М. Оrnithine-аspartate as universal hepatoprotactor-detoxicant with pleiothropic effect. Zdorovie Ukraina. 2013. № 9. P. 60–62. (in Russ)
  53. Ermolova T., Ermolov S., Dobkes A. et al. Pharmacological correction of intrahepatic vascular disorders. Abstracts of EASL monothematic conference “Portal hypertension” Budapest (Hungary). Jan. 22–24. 2009. no.20.
  54. Nadinskaya М. U. Hepa-Merz: biochemical properties and clinical effects.Moskva. 2008. (in Russ)
  55. Еrmolova Т. V., Еrmolov S. U., Belyaeva Е. L. NAFLD: modern view of the problem. Effektivnaya farmakoterapia. Gastroenterologia.2015. № 3 (33). P. 12–21. (in Russ).
Full text is published :
SOME MECHANISMS OF INTRAHEPATIC HEMODYNAMIC DISORDERS AND ITS CORRECTION IN CHRONIC LIVER DISEASES WITH AN INITIAL STAGE OF FIBROSIS. Experimental and Clinical Gastroenterology Journal. 2018;150(02):183-191
Read & Download full text

26.Title page: EVOLUTION OF VIEWS ON PROBLEMS OF HUMAN-SCAMMARY DISEASE IN PERM REGION
Palatova L. F.^1,2, Kotelnikova L. P.^1,2, Nechaev O. I. ^1,2 📧 .
1. Perm State Medical University. Acad. E. A. Wagner (Perm, Russian Federation)
2. Perm National Research Polytechnic University (Perm, Russian Federation)
Keywords:Gallstone disease,the composition of concrements,postcholecystectomy syndrome,holedohoduodenoanastomoz,cholecystolithiasis,cholangitis,mechanical jaundice

Abstract:Gallstone disease has been known since ancient times. In the XIX century, two theories of the appearance of gallstones were proposed: the primary pathology of the liver and stagnation in the gallbladder. Later, they were supplemented by ideas of participation of a microbial agent and violation of cholesterol metabolism. In the XX century, cholestotomy, cholecystostomy and cholecystectomy were performed. Differences in the quality of stones have been noted for a long time. Elemental composition of different stones in the form was the same. By the 1980s of the twentieth century there were three main theories of the pathogenesis of gastrointestinal tract: infectious, bile stagnation and lipid metabolism disorders. None of them solved the problem. Pathogenesis remained at the level of assumptions. The results of surgical treatment of calculous cholecystitis did not always match the expected results. The term “postcholecystectomy syndrome” was proposed to characterize pathological conditions after surgical treatment of gallbladder diseases. In the Perm State Medical Institute, a number of works appeared at the Department of Hospital Surgery, in which the correlation of clinical, biochemical and morphological changes in the liver with cholelithiasis was investigated. L. F. Palatova laid the direction of studying the relationship of standing of the liver and the course of cholelithiasis. L. P. Kotelnikova, based on the spectral study of concrements, it was suggested that they are formed as a result of a lipid distress syndrome, where the liver and biliary tract serve as the target organ. The peculiarities of ultrastructural changes were discovered by T. I. Subbotin in persons with SCI who had previously suffered hepatitis B. Disturbances of blood supply and microcirculation in stenoses of the fat nipple and choledocholithiasis are studied in the candidate’s thesis by V. M. Rusinov. A. V. Popov and D. V. Shvarev investigated the polymorphism in CHD, indications for surgery and the results of treatment and rehabilitation, including resort. L. B. Guschensky shows the relationship of pathological processes in HDB and pancreatitis. Complications of choledocholithiasis, in particular, cholangitis, are covered in the work of D. I. Dremin. The role of the intestinal microbiota in the course of pathological processes in the biliary tract was studied by NA. Zubareva. The influence of pre-operative dispensary, surgical tactics on the outcomes of treatment is shown in doctoral dissertations. Kotelnikova and P. Ya. Sandakova. The idea of the pathogenesis and course of CSF has come a long way, and there are still unresolved issues in this problem, and surgical treatment has also evolved from large surgical interventions to stage manipulations from small accesses, which allows the patient to escape from extensive operational trauma, shortens treatment time and improves the quality of life.
- References total 31 ⇓ :: .
  1. Fedorov S. P. Zhelchnye kamni i khirurgiya zhelchnykh putei / M. – L., Medgiz, 1934
  2. Galkin V.A., Lindenbraten L. D. Loginov A. S. Raspoznavanie i lechenie kholetsistita / M. Meditsina. 1972
  3. Sitenko V.M., Nechai A. I. Postkholetsistektomicheskii sindrom i povtornye operatsii na zhelchnykh putyakh / L-d, Meditsina. 1972
  4. Malle-Gi P. i Kestens P. Zh. Sindrom posle kholetsistektomii / M. Meditsina, 1973
  5. Palatova L. F. Khirurgicheskie zabolevaniya zhelchnykh putei, soprovozhdayushchiesya zheltukhoi, ikh vzaimosvyaz' s patologiei pecheni / avtoref. diss. d-ra med. nauk., Perm', 1977
  6. Dederer Yu.M., Krylova N. P., Ustinov G. G. Zhelchnokamennaya bolezn' / M. Meditsina. 1983
  7. Vetshev P.S., Shkrob O. S., Bel'tsovich D. G. Zhelchnokamennaya bolezn' / M. ZAO “Meditsinskaya gazeta”, 1998
  8. Subbotina T. I. Morfofunktsional'nye izmeneniya pecheni kak faktor patogeneza zhelchnokamennoi bolezni i vozmozhnost' ikh korrektsii /avtoref. diss. d-ra med. nauk, Tula, 1998
  9. Sherlok Sh., Duli Dzh. Zabolevaniya pecheni i zhelchnykh putei / M. Geotar-Meditsina, 1999
  10. Kharitonova L. A. Algoritm nablyudeniya za det'mi s zhelchnokamennoi bolezn'yu / Gastrobyulleten', 2001, № 4, s. 18–19
  11. Kotel'nikova L. P. Izmeneniya khimicheskogo sostava zhelchi i zhelchnykh kamnei pri kholelitiaze v zavisimosti ot patologii pecheni / avtoref. diss. kand. med. nauk. Perm', 1985
  12. Rusinov V. M. Otsenka sostoyaniya gepatobiliarnoi sistemy pri neopukholevykh porazheniyakh vnepechenochnykh zhelchnykh protokov, soprovozhdayushchikhsya narusheniem ottoka zhelchi / avtoref. diss. kand. med nauk, Perm', 1990
  13. Kotel'nikova L. P. Sostoyanie pecheni i zhelchnykh putei v otsenke khirurgicheskoi taktiki pri zhelchnokamennoi bolezni / avtoref. diss. d-ra med. nauk. Perm', 1995
  14. Khlebnikov V. V. Rezul'taty khirurgicheskogo lecheniya zhelchnokamennoi bolezni v zavisimosti ot sostoyaniya pecheni po dannym biokhimicheskikh i morfologicheskikh issledovanii /avtoref. diss. kand. med. nauk, Perm', 1995
  15. Dremin D. I. Diagnostika i lechenie kholangita u bol'nykh zhelchnokamennoi bolezn'yu v posleoperatsionnom periode / avtoref. diss. kand. med. nauk. Perm'. 1999
  16. Gushchenskii L. B. Diagnostika biliarnogo pankreatita i kholangita, i taktika vedeniya posleoperatsionnogo perioda u bol'nykh kholelitiazom / avtoref. diss. kand. med. nauk, Perm', 2003
  17. Shvarev D. V. Rezul'taty khirurgicheskogo lecheniya bol'nykh kholelitiazom s sochetannoi patologiei pecheni, zheludka, dvenadtsatiperstnoi kishki i podzheludochnoi zhelezy / avtoref. diss. kand. med. nauk, Perm', 2004
  18. Popov A. V. Prichiny neudovletvoritel'nykh rezul'tatov khirurgicheskogo lecheniya zhelchnokamennoi bolezni v sochetanii s patologiei zheludka, dvenadtsatiperstnoi kishki i pecheni / avtoref. diss. d-ra med. nauk, Perm', 2005.
  19. Palatova L.F., Kotel'nikova L.P., Popov A. V., Freind G. G., Rusinov V. M. Patologiya pecheni pri zhelchnokamennoi bolezni / Perm',2008
  20. Popper H., Schaffner H. Liver: structure and function / London, 1957
  21. Grunhage F., Lammer F. Gallstoun disease Patogenesis of gallstones A genetic perspective /Best Prakt Res Clin Gastroenterol. 2006, 20 (6), 997–1015
  22. Novacek G. Gender and gallstone disease / Wien med Wochenschrift 2006 156 527–533
  23. Klass D M Lauer N Hay B Kratzer W Fuchs V Arg64 variant of the beta3-adrenergic associated with gallstone formation / Am J Gastroenterol 2007 102 2482–2487
  24. Xu Z., Wang LX, Zwang NW, Hou CS, Ling XF, Xu Y, Zhou XY. Clinical application of shock wave lithotripsy in treating impacted stone in the bile duct system /World J Gastroenterol, 2006, 12, 130–133
  25. Grunhage F., Lammert F. Pathogenesis of gallstones: A genetic perspective /Best Pract Res Clin Gastroenterol,2006,20(6), 997–1015
  26. Poddar U. Gallstone disease in children /Indian Pediatr, 2010, 47, 945–953
  27. Kaur T. Kaur S. pathophisiological conditions in cholelithiasis formation in North Indian population spectroscopic biophysical and biochemical studi /Biol Trace Elem Res, 2010, 138
  28. Wittenburg H. Hereditary liver disease gallstones / Best Pract Res Clin Gastroenterol, 2010, 24(5), 747–756
  29. Reshetnyak V. I. Concept of the pathogenesis and treatment of cholelithiasis /World J Hepatol, 2012, 4(2), 18–34
  30. Alkhamesi N.A., Davies W. T., Pinto R. F., Schlachta C. M. Robot-assistant common bile duct exploration as an option for complex choledocholithiasis / Surg Endosc 2013, 27, 263–266
  31. Costi R. Sarli L. Diagnosis and management of choledocholithiasis in golden of imaging endoscopy and laparoscopy / World J Gastroenterol, 2014, 20(37), 13382–13401
Full text is published :
MEVOLUTION OF VIEWS ON PROBLEMS OF HUMAN-SCAMMARY DISEASE IN PERM REGION. Experimental and Clinical Gastroenterology Journal. 2018;150(02):192-198
Read & Download full text

27. Title page : In memory of Professor Nikolai Alekseevich Mukhin
Lazebnik L.B. ¹ 📧 .
1. FGBOU VPO MGMSU named after A. I. Evdokimov of the Ministry of Health of Russia (Moscow, Russian Federation)
Abstract:The article is devoted to the life and professional milestones of famous Russian physician and scientist, professor Nikolai Alekseevich Mukhin, Winner of the State Prize of the USSR, Honored Scientist of the Russian Federation, Academician of the Russian Academy of Medical Sciences, Doctor of Medical Sciences.

Full text is published :
MEMORY OF NIKOLAYA A. MUKHIN. Experimental and Clinical Gastroenterology Journal. 2018;150(02):199-200
Read & Download full text

№ 02 (150) 2018

LEADING ARTICLE

CLINICAL GASTROENTEROLOGY

SURGICAL GASTROENTEROLOGY

EXPERIENCE EXCHANGE

EXPERIMENTAL GASTROENTEROLOGY

LECTION

REVIEW

CLINICAL CASES

CLINICAL PHARMACOLOGY

HISTORY OF MEDICINE

INFORMATION